<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crvw="http://careviewinc.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crvw-20210930.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-11-10</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SeniorSecuredNotesRelatedPartyCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SeniorSecuredNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeniorSecuredNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SeniorSecuredConvertibleNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SeniorSecuredConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeniorSecuredConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_SoftwareBundleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SoftwareBundleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SoftwareBundleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SoftwareBundleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_SalesBasedContractRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SalesBasedContractRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_SubscriptionAndCirculationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:SubscriptionAndCirculationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_SubscriptionAndCirculationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:SubscriptionAndCirculationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_YearOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_YearTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_YearThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorPartnersWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorPartnersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorHybridWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorHybridWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_NetworkEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:NetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NetworkEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:NetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PatentsTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">crvw:PatentsTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PatentsTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">crvw:PatentsTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_DeferredInstallationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredInstallationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PrepaidLicenseFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:PrepaidLicenseFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DeferredInstallationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredInstallationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PrepaidLicenseFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:PrepaidLicenseFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-27_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="AsOf2015-06-26_custom_PDLBioPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-26</instant>
        </period>
    </context>
    <context id="AsOf2015-06-26_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-26</instant>
        </period>
    </context>
    <context id="From2015-10-082019-05-13_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-08</startDate>
            <endDate>2019-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="From2019-01-302019-01-31_custom_TenthPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:TenthPDLModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="From2018-02-272018-02-28_custom_EleventhPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:EleventhPDLModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-27</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="From2019-03-282019-03-29_custom_TwelfthPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:TwelfthPDLModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-28</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="From2019-04-282019-04-29_custom_ThirteenPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:ThirteenPDLModificationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-28</startDate>
            <endDate>2019-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-09_custom_FourthAmendmentToThePDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-09</instant>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheThreeLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_MediumTermNotes4Member_custom_MrJohnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotes4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">crvw:MrJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_MediumTermNotes4Member_custom_DrHigginsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotes4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">crvw:DrHigginsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FifthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheThreeLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:TerminationDateAxis">crvw:TerminationDate6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:TerminationDateAxis">crvw:TerminationDate5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:TerminationDateAxis">crvw:TerminationDate4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:TerminationDateAxis">crvw:TerminationDate7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:FourteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="From2020-01-272020-01-28_custom_NineteenthAmendmentToThePDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:NineteenthAmendmentToThePDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-01-28</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_MrJohnsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">crvw:MrJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">crvw:DrHigginsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:SixthPDLCreditAgreementAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:MediumTermNotesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">crvw:DrHigginsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PDLBioPharmaIncMember_custom_WarrantPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:WarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_PDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_PDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-04-21</instant>
        </period>
    </context>
    <context id="AsOf2011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-04-21</instant>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_FirstFiveYearNotePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">crvw:FirstFiveYearNotePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_SecondFiveYearNotePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">crvw:SecondFiveYearNotePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="AsOf2012-01-31_custom_HealthCor4Member_custom_ConvertibleDebt4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-01-31</instant>
        </period>
    </context>
    <context id="AsOf2012-01-31_custom_HealthCor4Member_custom_ConvertibleDebt5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-01-31</instant>
        </period>
    </context>
    <context id="AsOf2014-01-16_custom_HealthCor6Member_custom_ConvertibleDebt7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-16</instant>
        </period>
    </context>
    <context id="AsOf2014-01-16_custom_HealthCor6Member_custom_ConvertibleDebt6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-16</instant>
        </period>
    </context>
    <context id="From2014-01-152014-01-16_custom_HealthCor6Member_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-15</startDate>
            <endDate>2014-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2014-12-04_custom_HealthCor7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-04</instant>
        </period>
    </context>
    <context id="From2014-12-032014-12-04_custom_HealthCor7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-03</startDate>
            <endDate>2014-12-04</endDate>
        </period>
    </context>
    <context id="AsOf2018-02-23_custom_HealthCor10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-23</instant>
        </period>
    </context>
    <context id="From2018-02-222018-02-23_custom_HealthCor10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-22</startDate>
            <endDate>2018-02-23</endDate>
        </period>
    </context>
    <context id="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNinthAmedmentPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-09</startDate>
            <endDate>2018-07-10</endDate>
        </period>
    </context>
    <context id="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNinthAmedmentPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crvw:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-09</startDate>
            <endDate>2018-07-10</endDate>
        </period>
    </context>
    <context id="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNinthAmedmentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-09</startDate>
            <endDate>2018-07-10</endDate>
        </period>
    </context>
    <context id="AsOf2018-07-13_custom_HealthCorTenthAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorTenthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-13</instant>
        </period>
    </context>
    <context id="From2018-07-122018-07-13_custom_HealthCorTenthAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorTenthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-12</startDate>
            <endDate>2018-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_HealthCor14Member_custom_HealthCorNewInvestors1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor14Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNewInvestors1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="From2019-05-142019-05-15_custom_HealthCor14Member_custom_HealthCorNewInvestors1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor14Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNewInvestors1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_HealthCorThirteenMember_custom_HealthCorNewInvestorsOne1Member_custom_ThirteenthAmendmentNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNewInvestorsOne1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:ThirteenthAmendmentNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-17</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-17</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNotes2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:Investors2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNotes2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2018InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:February2018InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_July2018InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:July2018InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:Investors2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2020InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:February2020InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_HealthCor3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_HealthCor3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCor10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCorNinthAmedmentPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNinthAmedmentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:SecondRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:ThirdRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:FourthRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:FifthRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-03-032020-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-03-03</startDate>
            <endDate>2020-03-04</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-03-04</instant>
        </period>
    </context>
    <context id="AsOf2020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PayrollProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="From2020-04-092020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PayrollProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2009-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2009-09-08</instant>
        </period>
    </context>
    <context id="From2009-09-072009-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2009-09-07</startDate>
            <endDate>2009-09-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-09-30">0001377149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-09-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0020">CareView Communications Inc</dei:EntityRegistrantName>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:OtherNonoperatingIncomeNet
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:CapitalExpendituresFundedByTermLoan
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:RemeasurementOfOperatingLease
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_us-gaap_EquipmentMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_SoftwareBundleMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_SalesBasedContractRevenueMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:CostOfGoodsSoldSalesBasedEquipment
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2019-12-31_custom_SalesBasisContractMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2020-01-012020-09-30_custom_SalesBasisContractMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2020-01-012020-09-30_custom_SalesBasisContractMember"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-09-30_custom_SalesBasisContractMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="xdx2ixbrl0642"
      unitRef="USD">-195217275</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="xdx2ixbrl0644"
      unitRef="USD">-361594</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="xdx2ixbrl0646"
      unitRef="USD">294563</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="xdx2ixbrl0648"
      unitRef="USD">271067</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-03-04" id="xdx2ixbrl1082">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-03-04" id="xdx2ixbrl1111">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType contextRef="From2021-01-01to2021-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-09-30">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-09-30">000-54090</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-09-30">95-4659068</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-09-30">405 State Highway 121</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-09-30">Suite B-240</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-09-30">Lewisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-09-30">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-09-30">75067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-09-30">(972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-09-30">943-6050</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-11-10" decimals="INF" unitRef="Shares">139380748</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">271067</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">357950</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1471670</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1146486</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">392590</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">408450</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">347236</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">244307</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2482563</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2157193</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1279777</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1592484</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">943968</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">897712</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">582594</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">659099</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">211262</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">197121</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1737824</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1753932</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5500164</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5503609</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">396591</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">442004</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherShortTermBorrowings contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20013786</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">20163786</us-gaap:OtherShortTermBorrowings>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">700000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">700000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-09-30_custom_SeniorSecuredNotesRelatedPartyCurrentMember"
      decimals="0"
      unitRef="USD">479210</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2020-12-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember"
      decimals="0"
      unitRef="USD">1083599</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">56130924</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">44883349</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">159346</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">150087</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10714735</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7858480</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">88115382</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">74197706</us-gaap:LiabilitiesCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-09-30_custom_SeniorSecuredNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2020-12-31_custom_SeniorSecuredNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">749069</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">9894117</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-09-30_custom_SeniorSecuredConvertibleNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">2787693</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2020-12-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">3514921</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">23446963</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">20717036</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-09-30_custom_SeniorSecuredConvertibleNotesMember"
      decimals="0"
      unitRef="USD">254292</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2020-12-31_custom_SeniorSecuredConvertibleNotesMember"
      decimals="0"
      unitRef="USD">136810</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:SecuredLongTermDebt contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">3507983</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3394478</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">476309</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">561202</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">41092</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">27472347</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">34566833</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">115587729</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">108764539</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">139381</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">139381</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">84990329</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">84409372</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-195217275</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-187809683</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-110087565</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-103260930</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5500164</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5503609</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">2211951</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1566240</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6078167</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">4956909</us-gaap:Revenues>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">555489</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">791762</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1948850</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2265243</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">771313</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">709510</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2398305</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1994322</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">163809</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">136278</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">400143</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">379203</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">392574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">446429</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1179908</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1253638</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">187341</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">178142</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">512555</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">529313</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">2070526</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">2262121</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6439761</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">6421720</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">141425</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-695881</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-361594</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1464811</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">2041748</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">2657211</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">7045049</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">7906024</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">8</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">82</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">114</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">363</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2754</us-gaap:OtherNonoperatingExpense>
    <crvw:OtherNonoperatingIncomeNet
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">26310</crvw:OtherNonoperatingIncomeNet>
    <crvw:OtherNonoperatingIncomeNet
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-1063</crvw:OtherNonoperatingIncomeNet>
    <crvw:OtherNonoperatingIncomeNet
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">27013</crvw:OtherNonoperatingIncomeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-2041740</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-2630819</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-7045998</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-7881402</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-1900315</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-3326700</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-7407592</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-9346213</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-1900315</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-3326700</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-7407592</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-9346213</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84244343</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-176127037</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-91743313</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17342</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">17342</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8687</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">8687</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2944413</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">-2944413</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84270372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-179071450</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-94661697</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">18882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3075098</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-3075098</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84289254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-182146548</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-97717913</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">50029</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">50029</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3326700</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-3326700</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84339283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185473248</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-100994584</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84409372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-187809683</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-103260930</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52878</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">52878</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84462250</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-190296938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-105695307</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">54605</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">54605</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3020025</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3020025</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84936855</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-193316963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-108240727</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">53474</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">53474</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1900315</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-1900315</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84990329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-195217275</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-110087565</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-7407592</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-9346213</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">437859</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">483456</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">41820</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">45857</us-gaap:AmortizationOfIntangibleAssets>
    <crvw:AmortizationOfInstallationCosts
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">32876</crvw:AmortizationOfInstallationCosts>
    <crvw:AmortizationOfInstallationCosts
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">29102</crvw:AmortizationOfInstallationCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1963203</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">3396306</us-gaap:AmortizationOfDebtDiscountPremium>
    <crvw:AmortizationOfDeferredDebtIssuanceCosts
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">10970</crvw:AmortizationOfDeferredDebtIssuanceCosts>
    <crvw:AmortizationOfDeferredDebtIssuanceCosts
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">43352</crvw:AmortizationOfDeferredDebtIssuanceCosts>
    <crvw:NoncashLeaseExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">76505</crvw:NoncashLeaseExpense>
    <crvw:NoncashLeaseExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">84196</crvw:NoncashLeaseExpense>
    <us-gaap:PaidInKindInterest
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2222714</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2040334</us-gaap:PaidInKindInterest>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">580957</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">86257</us-gaap:StockOptionPlanExpense>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-2754</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">21886</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">325185</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-266830</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-15860</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">404750</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">102930</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">171226</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-12296</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">74903</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-45412</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-131503</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-2429662</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-2413914</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">426594</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">445160</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-75634</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">55802</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">294563</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-713390</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">82885</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">158679</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <crvw:PaymentsForDeferredInstallationCosts
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">59312</crvw:PaymentsForDeferredInstallationCosts>
    <crvw:PaymentsForDeferredInstallationCosts
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">8128</crvw:PaymentsForDeferredInstallationCosts>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">88075</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">137519</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-230272</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-304326</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">781800</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">150000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-1174</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-151174</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1181800</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-86883</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">164084</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">357950</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">269741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">271067</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">433825</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <crvw:CapitalExpendituresFundedByTermLoan
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">42266</crvw:CapitalExpendituresFundedByTermLoan>
    <crvw:RemeasurementOfOperatingLease
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">690568</crvw:RemeasurementOfOperatingLease>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zF24rsMRZGle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 1 &#x2013; &lt;span id="xdx_828_zrYeuOcRrOx1"&gt;BASIS OF PRESENTATION
AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfk4TGm4OPxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z2VtwZz0qLD1"&gt;Interim Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited interim condensed consolidated
financial statements of CareView Communications, Inc. (&#x201c;CareView&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;
or &#x201c;our&#x201d;) have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;)
for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments
(consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance
with GAAP and the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The balance sheet at December
31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information
and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual
results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the
full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on
April 8, 2021.&lt;/p&gt;

&lt;p id="xdx_857_zqeTs8SXXJR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="letter-spacing: -0.15pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--Covid19OutbreakPolicyTextBlock_zOVdylMUlmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zrZNFvayrgwh"&gt;COVID-19 Outbreak&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, a novel strain of coronavirus
(COVID-19) was identified in Wuhan, China, and has subsequently spread to other regions of the world, and has resulted in increased travel
restrictions, business disruptions and emergency quarantine measures across the world including the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has considered the effects of COVID-19
in the preparation of the financial statements as of and for the period ended September 30, 2021. We have been able to continue providing
services to our current customer base and have not yet experienced a slowdown in collections.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 27, 2020, the Coronavirus Aid, Relief,
and Economic Security (CARES) Act (the &#x201c;Act&#x201d;) was enacted. The CARES Act is an approximately $2 trillion emergency economic
stimulus package in response to the Coronavirus outbreak, which among other things contains numerous income tax provisions. Some of these
tax provisions were retroactively effective for years ending before the date of enactment.&lt;/p&gt;

&lt;p id="xdx_850_z3CcpCKvHCCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zrJuaYuLCr44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zJ5q5D83gOD2"&gt;Revenue Recognition &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We enter into contracts with customers that may
provide multiple combinations of our products, software solutions, and other related services which are generally capable of being distinct
and accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Customer contract fulfillment typically involves
multiple procurement promises which may include various equipment, software subscription, project-related installation and training services,
and support. We allocate the transaction price to each performance obligation based on estimated relative standalone selling price. Revenue
is then recognized for each performance obligation upon transferring control of the hardware, software, and services to the customer and
in an amount that reflects the consideration we expect to receive and the estimated benefit the customer receives over the term of the
contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;










&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Generally, we recognize revenue under ASC Topic
606 for each of our performance obligations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Subscription services &#x2013; We recognize subscription revenues monthly over the contracted license period.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Equipment packages &#x2013; We recognize equipment revenues when control of the devices has been
                                                                     transferred to the client (&#x201c;point in time&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Software bundle and related services &#x2013; We recognize our software subscription, installation, training,
and other services on a straight-line basis over the estimated contracted license period (&#x201c;over time&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are recognized net of any taxes collected
from customers and subsequently remitted to governmental authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjvWVJEIbMBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zMbBzRoMF8t"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 54%; text-align: justify"&gt;Equipment package (point in time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zEHpi2ydUKik" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Gross revenue"&gt;1,775,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zhd8xjZH5zal" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Software bundle (over time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zGNOdMrsl048" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;336,819&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zhCz5z93OmA2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0557"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify"&gt;Total sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_z33tkQEFZrh1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,112,443&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zCRapJ5TvUGf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_z4L03CUTl9Zc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,063,182&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_zIkwihFKSi2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Gross revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210930_zJ9E8AeVnlXa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,175,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20200101__20200930_zzbR1CsMaBXc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cost of goods sold (sales-based equipment only)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20210101__20210930_zCHosUJqEye" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of goods sold (sales-based equipment only)"&gt;97,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20200101__20200930_zubhybSqL071" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0566"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Revenue, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_iT_mtRev_c20210101__20210930_zoXdNIBmWxJ6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue, net"&gt;6,078,167&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_iT_mtRev_c20200101__20200930_zjWLa5o8PfX" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zQYCHO4b2fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our subscription-based contracts payment arrangements
are required to be paid monthly which are recognized into revenue when received. Some customers chose to pay their subscription fee in
advance. Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities.
These amounts are recorded as &#x201c;Deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized into revenues
over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our sales-based contract payment arrangements
with our customers typically include an initial equipment payment due upon signing of the contract and subsequent payments when certain
performance obligations are completed. Customer payments received in advance of satisfaction of related performance obligations are deferred
as contract liabilities. These amounts are recorded as &#x201c;Deferred revenue&#x201d; in our condensed consolidated balance sheet and
recognized into revenues as either a point in time or over time.&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zQaTQEu5WZh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zMPwalGv9gMh" title="Contract liability recognized as revenue"&gt;149,863&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zJwWhWeUNeui"&gt;117,325&lt;/span&gt;, respectively, of the beginning balance of the subscription-based contract liability was recognized
as revenue. The table below details the subscription-based contract liability activity during the nine months ended September 30, 2021,
and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B6_zFYx0zsa0JUl" style="display: none; visibility: hidden"&gt;Schedule of contract liability activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zBsOQuSnxqP6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zUJpBsS2V3Z2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zxhDLKTHUTdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;255,398&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zkrtHFnWm1F3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;220,696&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;422,715&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zR5D2CJoTQY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(220,375&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(288,156&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zPuD1zLr7y7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;238,584&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;389,957&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zkh1xbThnEXb" title="Contract liability recognized as revenue"&gt;221,312&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_d0_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zX4ZjIn3QPC5"&gt;0&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the nine months ended September 30, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpWbdhaM1i02" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zo4pRp9GSvc6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zlRvzq2603Vj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zMepEcSiYsph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,419,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0598"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zQpRSlFfX2Il" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,112,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zUdlpuWLW3z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;534,146&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0604"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z8wEta6cnfJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zVeIzH0PgVKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zNTUf6lSNd5l"&gt;As of September 30, 2021, the aggregate amount
of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied
or partially satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_901_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zDarxbwvDYkl" title="Performance obligations"&gt;772,730&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearOneMember_zwFdO9KAwtTf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;210,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearTwoMember_zaeubSxTM4ie" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,596&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearThreeMember_zThwyqV5pqYd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;85,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zB0JDix4d9X1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;772,730&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zUMnJZgQRxne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--CapitalizedContractCostTableTextBlock_zkHd1YyMG5Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We defer and capitalize all costs associated with
the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the
healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers
or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line
basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated
statements of operations. &lt;span id="xdx_8B1_zUk55NRUoYQ"&gt;The table below details the activity in these deferred installation costs during the nine months ended September
30, 2021, and 2020, included in other assets in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20210101__20210930_zncimxsUzqil" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20200101__20200930_zNdOqiePfv52" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Nine Months
    Ended &lt;br/&gt;September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zxPAAn1CzwQb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;54,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;81,188&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AdditionsToDeferredCosts_z7GcJA79stb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,128&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TransferToExpense_iN_di_zT8NoPH3MyM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(32,877&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(50,988&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedContractCostGross_iE_zm5BGfXLnxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;38,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_z46TOzHoHFD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Significant Judgements When Applying Topic
606&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contracts with our customers are typically structured
similarly and include various combinations of our products, software solutions, and related services. Determining whether the various
contract promises are considered distinct performance obligations that should be accounted for separately versus together may require
significant judgment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contract transaction price is allocated to distinct
performance obligations using estimated standalone selling price. We determine standalone selling price maximizing observable inputs such
as standalone sales, competitor standalone sales, or substantive renewal prices charged to customers when they exist. In instances where
standalone selling price is not observable, we utilize an estimate of standalone selling price. Such estimates are derived from various
methods that include cost plus margin, and historical pricing practices. Judgment may be required to determine standalone selling prices
for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contract modifications occur when we and our customers
agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some,
or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine
if the modification should be accounted for as a separate contract, the termination of the original contract and creation of a new contract,
a cumulative catch-up adjustment to the original contract, or a combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contracts with our customers include a limited
warranty on our products covering materials, workmanship, or design for the duration of contract. We do not offer paid additional extended
or lifetime warranty packages. We determined the limited warranty in our contract is not a distinct performance obligation. We do not
believe our estimates of warranty costs to be significant to our determination of revenue recognition and, therefore, did not reserve
for warranty costs.&lt;/p&gt;

&lt;p id="xdx_856_zTkcru9pWvn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zh0OVAlqeoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zx3WBJsOu7f5"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate earnings per share (&#x201c;EPS&#x201d;)
in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based
on the weighted average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number
of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method.
Such potential dilutive common shares consist of stock options, warrants to purchase our Common Stock (the &#x201c;Warrants&#x201d;) and
convertible debt. Potential common shares totaling approximately &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210930_zsMtEoLdU7P2" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;222,000,000&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200930_zLIIpu0SHFM9"&gt;203,000,000&lt;/span&gt; at September 30, 2021 and 2020, respectively,
have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.&lt;/p&gt;

&lt;p id="xdx_857_zZVho8HXMHp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfk4TGm4OPxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z2VtwZz0qLD1"&gt;Interim Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited interim condensed consolidated
financial statements of CareView Communications, Inc. (&#x201c;CareView&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;
or &#x201c;our&#x201d;) have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;)
for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments
(consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance
with GAAP and the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The balance sheet at December
31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information
and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual
results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the
full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on
April 8, 2021.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <crvw:Covid19OutbreakPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_849_ecustom--Covid19OutbreakPolicyTextBlock_zOVdylMUlmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zrZNFvayrgwh"&gt;COVID-19 Outbreak&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, a novel strain of coronavirus
(COVID-19) was identified in Wuhan, China, and has subsequently spread to other regions of the world, and has resulted in increased travel
restrictions, business disruptions and emergency quarantine measures across the world including the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has considered the effects of COVID-19
in the preparation of the financial statements as of and for the period ended September 30, 2021. We have been able to continue providing
services to our current customer base and have not yet experienced a slowdown in collections.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 27, 2020, the Coronavirus Aid, Relief,
and Economic Security (CARES) Act (the &#x201c;Act&#x201d;) was enacted. The CARES Act is an approximately $2 trillion emergency economic
stimulus package in response to the Coronavirus outbreak, which among other things contains numerous income tax provisions. Some of these
tax provisions were retroactively effective for years ending before the date of enactment.&lt;/p&gt;

</crvw:Covid19OutbreakPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zrJuaYuLCr44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zJ5q5D83gOD2"&gt;Revenue Recognition &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We enter into contracts with customers that may
provide multiple combinations of our products, software solutions, and other related services which are generally capable of being distinct
and accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Customer contract fulfillment typically involves
multiple procurement promises which may include various equipment, software subscription, project-related installation and training services,
and support. We allocate the transaction price to each performance obligation based on estimated relative standalone selling price. Revenue
is then recognized for each performance obligation upon transferring control of the hardware, software, and services to the customer and
in an amount that reflects the consideration we expect to receive and the estimated benefit the customer receives over the term of the
contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;










&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Generally, we recognize revenue under ASC Topic
606 for each of our performance obligations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Subscription services &#x2013; We recognize subscription revenues monthly over the contracted license period.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Equipment packages &#x2013; We recognize equipment revenues when control of the devices has been
                                                                     transferred to the client (&#x201c;point in time&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Software bundle and related services &#x2013; We recognize our software subscription, installation, training,
and other services on a straight-line basis over the estimated contracted license period (&#x201c;over time&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues are recognized net of any taxes collected
from customers and subsequently remitted to governmental authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 51pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjvWVJEIbMBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zMbBzRoMF8t"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 54%; text-align: justify"&gt;Equipment package (point in time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zEHpi2ydUKik" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Gross revenue"&gt;1,775,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zhd8xjZH5zal" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Software bundle (over time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zGNOdMrsl048" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;336,819&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zhCz5z93OmA2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0557"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify"&gt;Total sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_z33tkQEFZrh1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,112,443&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zCRapJ5TvUGf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_z4L03CUTl9Zc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,063,182&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_zIkwihFKSi2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Gross revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210930_zJ9E8AeVnlXa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,175,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20200101__20200930_zzbR1CsMaBXc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cost of goods sold (sales-based equipment only)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20210101__20210930_zCHosUJqEye" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of goods sold (sales-based equipment only)"&gt;97,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20200101__20200930_zubhybSqL071" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0566"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Revenue, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_iT_mtRev_c20210101__20210930_zoXdNIBmWxJ6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue, net"&gt;6,078,167&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_iT_mtRev_c20200101__20200930_zjWLa5o8PfX" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zQYCHO4b2fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our subscription-based contracts payment arrangements
are required to be paid monthly which are recognized into revenue when received. Some customers chose to pay their subscription fee in
advance. Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities.
These amounts are recorded as &#x201c;Deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized into revenues
over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our sales-based contract payment arrangements
with our customers typically include an initial equipment payment due upon signing of the contract and subsequent payments when certain
performance obligations are completed. Customer payments received in advance of satisfaction of related performance obligations are deferred
as contract liabilities. These amounts are recorded as &#x201c;Deferred revenue&#x201d; in our condensed consolidated balance sheet and
recognized into revenues as either a point in time or over time.&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zQaTQEu5WZh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zMPwalGv9gMh" title="Contract liability recognized as revenue"&gt;149,863&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zJwWhWeUNeui"&gt;117,325&lt;/span&gt;, respectively, of the beginning balance of the subscription-based contract liability was recognized
as revenue. The table below details the subscription-based contract liability activity during the nine months ended September 30, 2021,
and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B6_zFYx0zsa0JUl" style="display: none; visibility: hidden"&gt;Schedule of contract liability activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zBsOQuSnxqP6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zUJpBsS2V3Z2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zxhDLKTHUTdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;255,398&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zkrtHFnWm1F3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;220,696&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;422,715&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zR5D2CJoTQY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(220,375&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(288,156&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zPuD1zLr7y7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;238,584&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;389,957&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zkh1xbThnEXb" title="Contract liability recognized as revenue"&gt;221,312&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_d0_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zX4ZjIn3QPC5"&gt;0&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the nine months ended September 30, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpWbdhaM1i02" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zo4pRp9GSvc6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zlRvzq2603Vj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zMepEcSiYsph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,419,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0598"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zQpRSlFfX2Il" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,112,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zUdlpuWLW3z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;534,146&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0604"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z8wEta6cnfJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zVeIzH0PgVKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zNTUf6lSNd5l"&gt;As of September 30, 2021, the aggregate amount
of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied
or partially satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_901_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zDarxbwvDYkl" title="Performance obligations"&gt;772,730&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearOneMember_zwFdO9KAwtTf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;210,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearTwoMember_zaeubSxTM4ie" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,596&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearThreeMember_zThwyqV5pqYd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;85,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zB0JDix4d9X1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;772,730&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zUMnJZgQRxne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--CapitalizedContractCostTableTextBlock_zkHd1YyMG5Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We defer and capitalize all costs associated with
the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the
healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers
or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line
basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated
statements of operations. &lt;span id="xdx_8B1_zUk55NRUoYQ"&gt;The table below details the activity in these deferred installation costs during the nine months ended September
30, 2021, and 2020, included in other assets in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20210101__20210930_zncimxsUzqil" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20200101__20200930_zNdOqiePfv52" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Nine Months
    Ended &lt;br/&gt;September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zxPAAn1CzwQb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;54,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;81,188&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AdditionsToDeferredCosts_z7GcJA79stb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,128&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TransferToExpense_iN_di_zT8NoPH3MyM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(32,877&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(50,988&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedContractCostGross_iE_zm5BGfXLnxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;38,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_z46TOzHoHFD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Significant Judgements When Applying Topic
606&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contracts with our customers are typically structured
similarly and include various combinations of our products, software solutions, and related services. Determining whether the various
contract promises are considered distinct performance obligations that should be accounted for separately versus together may require
significant judgment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contract transaction price is allocated to distinct
performance obligations using estimated standalone selling price. We determine standalone selling price maximizing observable inputs such
as standalone sales, competitor standalone sales, or substantive renewal prices charged to customers when they exist. In instances where
standalone selling price is not observable, we utilize an estimate of standalone selling price. Such estimates are derived from various
methods that include cost plus margin, and historical pricing practices. Judgment may be required to determine standalone selling prices
for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contract modifications occur when we and our customers
agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some,
or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine
if the modification should be accounted for as a separate contract, the termination of the original contract and creation of a new contract,
a cumulative catch-up adjustment to the original contract, or a combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Contracts with our customers include a limited
warranty on our products covering materials, workmanship, or design for the duration of contract. We do not offer paid additional extended
or lifetime warranty packages. We determined the limited warranty in our contract is not a distinct performance obligation. We do not
believe our estimates of warranty costs to be significant to our determination of revenue recognition and, therefore, did not reserve
for warranty costs.&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjvWVJEIbMBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zMbBzRoMF8t"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 54%; text-align: justify"&gt;Equipment package (point in time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zEHpi2ydUKik" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Gross revenue"&gt;1,775,624&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--EquipmentMember_zhd8xjZH5zal" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Software bundle (over time)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zGNOdMrsl048" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;336,819&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SoftwareBundleMember_zhCz5z93OmA2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0557"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify"&gt;Total sales-based contract revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_z33tkQEFZrh1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,112,443&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zCRapJ5TvUGf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_z4L03CUTl9Zc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,063,182&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--SubscriptionAndCirculationMember_zIkwihFKSi2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Gross revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210930_zJ9E8AeVnlXa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,175,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20200101__20200930_zzbR1CsMaBXc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cost of goods sold (sales-based equipment only)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20210101__20210930_zCHosUJqEye" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost of goods sold (sales-based equipment only)"&gt;97,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CostOfGoodsSoldSalesBasedEquipment_msRev_c20200101__20200930_zubhybSqL071" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0566"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt"&gt;Revenue, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Revenues_iT_mtRev_c20210101__20210930_zoXdNIBmWxJ6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue, net"&gt;6,078,167&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_iT_mtRev_c20200101__20200930_zjWLa5o8PfX" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,956,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-09-30_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1775624</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-09-30_custom_SoftwareBundleMember"
      decimals="0"
      unitRef="USD">336819</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-09-30_custom_SalesBasedContractRevenueMember"
      decimals="0"
      unitRef="USD">2112443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-09-30_us-gaap_SubscriptionAndCirculationMember"
      decimals="0"
      unitRef="USD">4063182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_us-gaap_SubscriptionAndCirculationMember"
      decimals="0"
      unitRef="USD">4956909</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6175625</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">4956909</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <crvw:CostOfGoodsSoldSalesBasedEquipment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">97458</crvw:CostOfGoodsSoldSalesBasedEquipment>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6078167</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">4956909</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zQaTQEu5WZh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zMPwalGv9gMh" title="Contract liability recognized as revenue"&gt;149,863&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zJwWhWeUNeui"&gt;117,325&lt;/span&gt;, respectively, of the beginning balance of the subscription-based contract liability was recognized
as revenue. The table below details the subscription-based contract liability activity during the nine months ended September 30, 2021,
and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B6_zFYx0zsa0JUl" style="display: none; visibility: hidden"&gt;Schedule of contract liability activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zBsOQuSnxqP6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zUJpBsS2V3Z2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zxhDLKTHUTdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;255,398&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zkrtHFnWm1F3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;220,696&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;422,715&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zR5D2CJoTQY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(220,375&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(288,156&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zPuD1zLr7y7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;238,584&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;389,957&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
and 2020, a total of $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zkh1xbThnEXb" title="Contract liability recognized as revenue"&gt;221,312&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_d0_c20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zX4ZjIn3QPC5"&gt;0&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the nine months ended September 30, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20210930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpWbdhaM1i02" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20200101__20200930__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zo4pRp9GSvc6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zlRvzq2603Vj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ContractWithCustomerLiabilityAdditions_zMepEcSiYsph" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,419,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0598"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zQpRSlFfX2Il" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,112,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iE_zUdlpuWLW3z5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;534,146&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0604"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2021-01-012021-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">149863</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2020-01-012020-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">117325</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-12-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">238263</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2019-12-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">255398</us-gaap:ContractWithCustomerLiability>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2021-01-012021-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">220696</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2020-01-012020-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">422715</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2021-01-012021-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">220375</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2020-01-012020-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">288156</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">238584</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-09-30_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">389957</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2021-01-012021-09-30_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">221312</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2020-01-012020-09-30_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-12-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">226861</us-gaap:ContractWithCustomerLiability>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2021-01-012021-09-30_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">2419328</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2021-01-012021-09-30_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">2112043</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-09-30_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">534146</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_897_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zVeIzH0PgVKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zNTUf6lSNd5l"&gt;As of September 30, 2021, the aggregate amount
of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied
or partially satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_901_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zDarxbwvDYkl" title="Performance obligations"&gt;772,730&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearOneMember_zwFdO9KAwtTf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;210,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearTwoMember_zaeubSxTM4ie" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,596&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930__custom--PerformanceDateAxis__custom--YearThreeMember_zThwyqV5pqYd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;85,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20210930_zB0JDix4d9X1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;772,730&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">772730</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2021-09-30_custom_YearOneMember"
      decimals="0"
      unitRef="USD">210554</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2021-09-30_custom_YearTwoMember"
      decimals="0"
      unitRef="USD">476596</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2021-09-30_custom_YearThreeMember"
      decimals="0"
      unitRef="USD">85580</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">772730</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CapitalizedContractCostTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89E_eus-gaap--CapitalizedContractCostTableTextBlock_zkHd1YyMG5Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We defer and capitalize all costs associated with
the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the
healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers
or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line
basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated
statements of operations. &lt;span id="xdx_8B1_zUk55NRUoYQ"&gt;The table below details the activity in these deferred installation costs during the nine months ended September
30, 2021, and 2020, included in other assets in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20210101__20210930_zncimxsUzqil" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20200101__20200930_zNdOqiePfv52" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Nine Months
    Ended &lt;br/&gt;September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zxPAAn1CzwQb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;54,003&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;81,188&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AdditionsToDeferredCosts_z7GcJA79stb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,128&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TransferToExpense_iN_di_zT8NoPH3MyM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Transfer to expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(32,877&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(50,988&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedContractCostGross_iE_zm5BGfXLnxuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;38,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:CapitalizedContractCostTableTextBlock>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">54003</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">81188</us-gaap:CapitalizedContractCostGross>
    <crvw:AdditionsToDeferredCosts
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">59312</crvw:AdditionsToDeferredCosts>
    <crvw:AdditionsToDeferredCosts
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">8128</crvw:AdditionsToDeferredCosts>
    <crvw:TransferToExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">32877</crvw:TransferToExpense>
    <crvw:TransferToExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">50988</crvw:TransferToExpense>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">80438</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">38328</us-gaap:CapitalizedContractCostGross>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zh0OVAlqeoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zx3WBJsOu7f5"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate earnings per share (&#x201c;EPS&#x201d;)
in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based
on the weighted average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number
of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method.
Such potential dilutive common shares consist of stock options, warrants to purchase our Common Stock (the &#x201c;Warrants&#x201d;) and
convertible debt. Potential common shares totaling approximately &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210930_zsMtEoLdU7P2" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;222,000,000&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200930_zLIIpu0SHFM9"&gt;203,000,000&lt;/span&gt; at September 30, 2021 and 2020, respectively,
have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">222000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">203000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <crvw:LiquidityAndManagmentsPlanTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_802_ecustom--LiquidityAndManagmentsPlanTextBlock_zEsnK30cV2z7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 2 &#x2013; &lt;span id="xdx_82F_zbAcfmWss4E8"&gt;GOING CONCERN, LIQUIDITY
AND MANAGEMENT&#x2019;S PLAN&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting standards require management to evaluate
whether the Company can continue as a going concern for a period of one year after the date of the filing of this Form 10-Q (&#x201c;evaluation
period&#x201d;). In evaluating the Company&#x2019;s ability to continue as a going concern, Management considers the conditions and events
that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of twelve months after the
Company issues its financial statements. For the period ended September 30, 2021, Management considers the Company&#x2019;s current financial
condition and liquidity sources, including current funds available, forecasted future cash flows, and the Company&#x2019;s conditional
and unconditional obligations due before November 10, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;








&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to risks like those of
healthcare technology companies whereby revenues are generated based on both on a sales-based and subscription-based business model such
as dependence on key individuals, uncertainty of product development, generation of revenues, positive cash flow, dependence on outside
sources of capital, risks associated with research, development, and successful testing of its products, successful protection of intellectual
property, ability to maintain and grow its customer base, and susceptibility to infringement on the proprietary rights of others. The
attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company&#x2019;s
growth and operating activities and generating a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has experienced net losses and significant
cash outflows from cash used in operating activities over the past years. As of and for the nine months ended September 30, 2021, the
Company had an accumulated deficit of approximately $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20210930_zIdzeizKBqlc" title="Accumulated deficit::XDX::-195%2C217%2C275"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;195,000,000&lt;/span&gt;&lt;/span&gt;, loss from operations of approximately $&lt;span id="xdx_900_eus-gaap--OperatingIncomeLoss_dxL_c20210101__20210930_zAxDXIyXGZ68" title="Income from operations::XDX::-361594"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;(362,000)&lt;/span&gt;&lt;/span&gt;, net cash provided
by operating activities of approximately $&lt;span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_dxL_c20210101__20210930_zeynG6MNLssh" title="Net cash provided by operating activities::XDX::294563"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;295,000&lt;/span&gt;&lt;/span&gt;, and an ending cash balance of approximately $&lt;span id="xdx_90B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_dxL_c20210930_z5w4BGyiE1V" title="Cash balance::XDX::271%2C067"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;271,000&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, the Company had cash
and a working capital deficit of approximately $&lt;span id="xdx_90A_ecustom--WorkingCapitalDeficit_iI_c20210930_zhOPDs2iHXJj" title="Working capital deficit"&gt;85,600,000&lt;/span&gt; consisting primarily of notes payables and senior secured notes. Management
has evaluated the significance of the conditions described above in relation to the Company&#x2019;s ability to meet its obligations and
concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the
date the condensed consolidated financial statements were issued. While management will look to continue funding operations by increased
sales volumes and raising additional capital from sources such as sales of its debt or equity securities or loans to meet operating cash
requirements, there is no assurance that management&#x2019;s plans will be successful.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management continues to monitor the immediate
and future cash flows needs of the company in a variety of ways which include forecasted net cash flows from operations, capital expenditure
control, new inventory orders, debt modifications, increases sales outreach, streamlining and controlling general and administrative costs,
competitive industry pricing, sale of equities, debt conversions, new product or services offerings, and new business partnerships.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s net losses, cash outflows,
and working capital deficit raise substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a
going concern. This basis of accounting contemplates the recovery of the Company&#x2019;s assets and the satisfaction of liabilities in
the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive
cash flows adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;

</crvw:LiquidityAndManagmentsPlanTextBlock>
    <crvw:WorkingCapitalDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">85600000</crvw:WorkingCapitalDeficit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zb4eWUfoom3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 3 &#x2013; &lt;span id="xdx_820_zpFYvb3c1Ri9"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Warrants to Purchase Common Stock of the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We use the Black-Scholes-Merton option pricing
model (&#x201c;Black-Scholes Model&#x201d;) to determine the fair value of Warrants (except Warrants issued to HealthCor in 2011 (the &#x201c;2011
HealthCor Warrants&#x201d;) as discussed in NOTE 11 and the warrants issued in connection with a private placement completed in April 2013
(&#x201c;Private Placement Warrants&#x201d;). The Black-Scholes Model requires the use of several assumptions including volatility of the
stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and
is calculated by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure
of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility
is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available)
over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the
lack of sufficient historical data of our stock price during 2007-2009. On April 20, 2021, we issued &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorPartnersWarrantsMember_zUC6Aj7zq3yj" title="Number of warrants issued"&gt;931,600&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorHybridWarrantsMember_zFeSMxnfE1Zh" title="Number of warrants issued"&gt;1,068,400&lt;/span&gt; warrants to
purchase our Common Stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorWarrantsMember_z6sKeGPFzLPa" title="Warrant exercise price (in dollars per share)"&gt;0.23&lt;/span&gt; per share to HealthCor Partners and HealthCor Hybrid, respectively. See NOTE 11.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zleT46W9T24e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zgsoT2UBMPX8"&gt;A summary of our Warrants activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number of Shares Under Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Range of &lt;br/&gt;Warrant Price &lt;br/&gt;Per
    Share&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pii_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOcWcIN0y1v" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Warrants outstanding, beginning"&gt;16,050,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zoQk9DylWS88" title="Warrant price, beginning"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5HhZ9c4x6Ji"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAverageExercisePriceWarrant_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zNyawSiBTpR9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Warrant exercise price, beginning"&gt;0.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightsContractualLifeBeginning_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9JWNwMwO78f" title="Warrant term, beginning"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightsWarrantsGranted_pid_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlSxPhKUulCi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td id="xdx_982_ecustom--RangeOfWarrantPricePerShareWarrantGranted_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfR1kRekFOAg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant price granted"&gt;$0.23&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsGranted_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zARwKvJVDv6c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightsContractualLifeGranted_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXbOOL8OBmK5" title="Warrant term, granted"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Canceled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pii_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zurljNz8Nin" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending"&gt;18,050,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJGSsAw1Qnd8" title="Warrant price, ending"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEn6h4KB4muh"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrant_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zy2IC0Cu7AE" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant exercise price, ending"&gt;0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightsContractualLifeEnding_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn156Se0MCYc" title="Warrant term, ending"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zkluskYOnXYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Options to Purchase Common Stock of the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30, 2021,
&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210930_zKYt2fjs4Wmi" title="Options granted"&gt;334,000&lt;/span&gt; Options to purchase our Common Stock (the &#x201c;Option(s)&#x201d;) were granted having a with a fair value of $&lt;span id="xdx_90A_ecustom--StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross_c20210101__20210930_zCzdtwfrb5lf" title="Options granted, fair value"&gt;38,015&lt;/span&gt; and exercise
prices of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20210101__20210930_zbzFR9NNwHXj" title="Option exercise prices, minimum"&gt;0.05&lt;/span&gt;-$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20210101__20210930_zEte5k5NXXSk" title="Option exercise prices, maximum"&gt;0.23&lt;/span&gt; per share. During the nine months ended September 30, 2021, Options totaling &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20210930_zB8Ly01CZBRj" title="Option forfeited"&gt;72,000&lt;/span&gt; were forfeited and &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20210101__20210930_zvlzFX14c3y7" title="Options terminated"&gt;258,491&lt;/span&gt; Options
were terminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zC83aIo8DPu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zcSCFlCPexy2"&gt;A summary of our stock option activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number of
    Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;
Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210930_zjwm2A1L46Fk" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;40,688,968&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zU8MGWdW0Aw7" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining_dtY_c20210101__20210930_zECGUJIwNjr9" title="Stock Options Outstanding, Beginning"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20210930_zZKGtAgXqgQl" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;526,724&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210930_zoLjLb21buR8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"&gt;334,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Forfeited/Terminated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20210930_zkeeW9Ur9lDb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited/Terminated"&gt;(330,491&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance at September 30, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_z0uECt2lhxYb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;40,692,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zRohzYyTc547" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;0.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20210930_zINF0yQntv2k" title="Stock Options Outstanding, Ending"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20210101__20210930_zdM3m8A3ppg1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;2,887,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Vested and Exercisable at September 30, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210930_zGvSk1Qfg4Md" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;26,262,144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210930_zuP9uwYAJNnj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;0.17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zffS4fkB4W5b" title="Stock Options, Vested and Exercisable"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20210101__20210930_z1bp08SmO6Hi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;2,865,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zH7kjSn84UD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Share-based compensation expense for Options charged
to our operating results for the nine months ended September 30, 2021, and 2020 ($&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930_zt5QGc0ni97f" title="Stock based compensation related to options granted"&gt;160,957&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930_z2hmp59GQuJb"&gt;86,257&lt;/span&gt;, respectively) is based over the
awards&#x2019; vested period. The estimate of forfeitures is to be recorded at the time of grant and revised in subsequent periods if actual
forfeitures differ from the estimates. We have not included an adjustment to our stock-based compensation expense based on the nominal
amount of the historical forfeiture rate. We do, however, revise our stock-based compensation expense based on actual forfeitures during
each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, total unrecognized estimated
compensation expense related to non-vested Options granted prior to that date was approximately $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20210930_zuu64WPHBLHk" title="Unrecognized estimated compensation expense"&gt;425,000&lt;/span&gt;, which is expected to be recognized
over a weighted-average period of &lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210930_zW0X9fPDOnN5" title="Period for recognition of unrecognized compensation expense"&gt;1.9&lt;/span&gt; years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-20_custom_HealthCorPartnersWarrantsMember"
      decimals="INF"
      unitRef="Shares">931600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-20_custom_HealthCorHybridWarrantsMember"
      decimals="INF"
      unitRef="Shares">1068400</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-04-20_custom_HealthCorWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zleT46W9T24e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zgsoT2UBMPX8"&gt;A summary of our Warrants activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number of Shares Under Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Range of &lt;br/&gt;Warrant Price &lt;br/&gt;Per
    Share&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pii_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOcWcIN0y1v" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Warrants outstanding, beginning"&gt;16,050,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zoQk9DylWS88" title="Warrant price, beginning"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5HhZ9c4x6Ji"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAverageExercisePriceWarrant_iS_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zNyawSiBTpR9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Warrant exercise price, beginning"&gt;0.76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightsContractualLifeBeginning_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9JWNwMwO78f" title="Warrant term, beginning"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightsWarrantsGranted_pid_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlSxPhKUulCi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td id="xdx_982_ecustom--RangeOfWarrantPricePerShareWarrantGranted_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfR1kRekFOAg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant price granted"&gt;$0.23&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsGranted_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zARwKvJVDv6c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightsContractualLifeGranted_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXbOOL8OBmK5" title="Warrant term, granted"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Canceled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pii_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zurljNz8Nin" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending"&gt;18,050,458&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJGSsAw1Qnd8" title="Warrant price, ending"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEn6h4KB4muh"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrant_iE_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zy2IC0Cu7AE" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant exercise price, ending"&gt;0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightsContractualLifeEnding_dtY_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn156Se0MCYc" title="Warrant term, ending"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">16050458</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvw:WeightedAverageExercisePriceWarrant
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.76</crvw:WeightedAverageExercisePriceWarrant>
    <crvw:ClassOfWarrantOrRightsContractualLifeBeginning contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember">P4Y</crvw:ClassOfWarrantOrRightsContractualLifeBeginning>
    <crvw:ClassOfWarrantOrRightsWarrantsGranted
      contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</crvw:ClassOfWarrantOrRightsWarrantsGranted>
    <crvw:RangeOfWarrantPricePerShareWarrantGranted
      contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.23</crvw:RangeOfWarrantPricePerShareWarrantGranted>
    <crvw:WarrantsGranted
      contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.74</crvw:WarrantsGranted>
    <crvw:ClassOfWarrantOrRightsContractualLifeGranted contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember">P9Y7M6D</crvw:ClassOfWarrantOrRightsContractualLifeGranted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">18050458</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvw:WeightedAverageExercisePriceWarrant
      contextRef="AsOf2021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.74</crvw:WeightedAverageExercisePriceWarrant>
    <crvw:ClassOfWarrantOrRightsContractualLifeEnding contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember">P4Y6M</crvw:ClassOfWarrantOrRightsContractualLifeEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <crvw:StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">38015</crvw:StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">258491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zC83aIo8DPu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zcSCFlCPexy2"&gt;A summary of our stock option activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number of
    Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;
Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210930_zjwm2A1L46Fk" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;40,688,968&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zU8MGWdW0Aw7" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;0.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining_dtY_c20210101__20210930_zECGUJIwNjr9" title="Stock Options Outstanding, Beginning"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20210101__20210930_zZKGtAgXqgQl" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Stock Options Outstanding, Beginning"&gt;526,724&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210930_zoLjLb21buR8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"&gt;334,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Forfeited/Terminated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20210930_zkeeW9Ur9lDb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited/Terminated"&gt;(330,491&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance at September 30, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_z0uECt2lhxYb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;40,692,477&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zRohzYyTc547" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;0.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20210930_zINF0yQntv2k" title="Stock Options Outstanding, Ending"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20210101__20210930_zdM3m8A3ppg1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;2,887,098&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Vested and Exercisable at September 30, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210930_zGvSk1Qfg4Md" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;26,262,144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210930_zuP9uwYAJNnj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;0.17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zffS4fkB4W5b" title="Stock Options, Vested and Exercisable"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20210101__20210930_z1bp08SmO6Hi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Vested and Exercisable"&gt;2,865,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">40688968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining contextRef="From2021-01-01to2021-09-30">P7Y7M6D</crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">526724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">330491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">40692477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-01to2021-09-30">P6Y10M24D</crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2887098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">26262144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-09-30">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2865858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">160957</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">86257</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">425000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-01-01to2021-09-30">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_ztijw5u0yOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 4 &#x2013; &lt;span id="xdx_828_z8zBsx5JHhr9"&gt;OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z8jYotx6MiZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zjmPRh5ErMaa"&gt;Other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zPgPr8bqyPA9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20201231_zlB1qfCuJH47" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_maOACzXKY_maOACzxxY_zz8BXbxuH6k6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;347,236&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;211,751&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAssetsMiscellaneousCurrent_iI_maOACzXKY_maOACzxxY_zXa3UDHpd1oh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other current assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,556&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsCurrent_iTI_mtOACzXKY_mtOACzxxY_zTOqcXPQOsRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;347,236&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;244,307&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zSkpvgrxMF85" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z8jYotx6MiZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zjmPRh5ErMaa"&gt;Other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zPgPr8bqyPA9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20201231_zlB1qfCuJH47" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_maOACzXKY_maOACzxxY_zz8BXbxuH6k6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;347,236&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;211,751&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAssetsMiscellaneousCurrent_iI_maOACzXKY_maOACzxxY_zXa3UDHpd1oh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other current assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,556&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsCurrent_iTI_mtOACzXKY_mtOACzxxY_zTOqcXPQOsRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;347,236&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;244,307&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">347236</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">211751</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">32556</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">347236</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">244307</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zvPgvfp06Tvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 5 &#x2013; &lt;span id="xdx_827_z97M5Fkt9Brd"&gt;INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory is valued at the lower of cost, determined
on a first-in, first-out (FIFO), or net realizable value. Inventory items are analyzed to determine cost and net realizable value and
appropriate valuation adjustments are then established.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z6gmLuWPQ7Di" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zy7rjeWr9uT3"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zC6GzfejOnKa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, &lt;br/&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_z1A1RoqsYZBk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, &lt;br/&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzxxr_maINzDRu_zRhjTcDndoVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Inventory assets (finished goods)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;392,590&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;408,450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtINzxxr_mtINzDRu_zTI5IUJfB2lh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;392,590&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;408,450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zVjNqRXuV8ya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z6gmLuWPQ7Di" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zy7rjeWr9uT3"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210930_zC6GzfejOnKa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, &lt;br/&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_z1A1RoqsYZBk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, &lt;br/&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzxxr_maINzDRu_zRhjTcDndoVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Inventory assets (finished goods)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;392,590&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;408,450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtINzxxr_mtINzDRu_zTI5IUJfB2lh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;392,590&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;408,450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">392590</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">408450</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">392590</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">408450</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ztrvRoPrDbWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 6 &#x2013; &lt;span id="xdx_820_zGLvEHWb8Aw5"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEFHbucAUWc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zEBuHARKukB2"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-left: 0pt"&gt;Network equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zrWiba71vqm1" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total property and equipment"&gt;12,824,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zGOtchh0gVyf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;12,740,878&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Office equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zjOJ48aPoiQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zfOHAiolVZ28" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Vehicles&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zn1rc7Ub0kPg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zS9DiRZ0BQNb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;217,004&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Furniture&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zTy4Fwd7uska" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zDQSTP8Vy2zj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Warehouse equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z2oriC64aSbi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4A0rTqEGYed" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zh4h5QOxB6pd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdBFy2N5IGx8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;TOTAL PROPERTY AND EQUIPMENT&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20210930_zsV3HwEQNeE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,393,856&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_ziVIdhhgRz51" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,294,613&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20210930_zbkG9U3ecrR7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: accumulated depreciation"&gt;(12,114,079&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zWshw1vfHvWa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(11,702,129&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL PROPERTY AND EQUIPMENT, NET&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20210930_zZuBmIqqAyFj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total property and equipment, net"&gt;1,279,777&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iTI_c20201231_zeKNbNvtIheb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,592,484&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zG0LeKzeFQw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense for the nine months ended
September 30, 2021, and 2020 was $&lt;span id="xdx_90D_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20210930_zKyqrkCBNb7b" title="Depreciation expense"&gt;437,859&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DepreciationDepletionAndAmortization_c20200101__20200930_zDI8uSkKd66c"&gt;483,456&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEFHbucAUWc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zEBuHARKukB2"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-left: 0pt"&gt;Network equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zrWiba71vqm1" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total property and equipment"&gt;12,824,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zGOtchh0gVyf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;12,740,878&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Office equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zjOJ48aPoiQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zfOHAiolVZ28" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Vehicles&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zn1rc7Ub0kPg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zS9DiRZ0BQNb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;217,004&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Furniture&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zTy4Fwd7uska" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zDQSTP8Vy2zj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Warehouse equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z2oriC64aSbi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4A0rTqEGYed" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zh4h5QOxB6pd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdBFy2N5IGx8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;TOTAL PROPERTY AND EQUIPMENT&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20210930_zsV3HwEQNeE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,393,856&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_ziVIdhhgRz51" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,294,613&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20210930_zbkG9U3ecrR7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: accumulated depreciation"&gt;(12,114,079&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zWshw1vfHvWa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(11,702,129&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL PROPERTY AND EQUIPMENT, NET&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20210930_zZuBmIqqAyFj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total property and equipment, net"&gt;1,279,777&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iTI_c20201231_zeKNbNvtIheb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,592,484&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_custom_NetworkEquipmentMember"
      decimals="0"
      unitRef="USD">12824714</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_NetworkEquipmentMember"
      decimals="0"
      unitRef="USD">12740878</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">229240</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">229240</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_us-gaap_VehiclesMember"
      decimals="0"
      unitRef="USD">232411</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_VehiclesMember"
      decimals="0"
      unitRef="USD">217004</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">92846</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">92846</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">9524</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">9524</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-09-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">5121</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">5121</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">13393856</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">13294613</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">12114079</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">11702129</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1279777</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1592484</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">437859</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">483456</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80B_eus-gaap--OtherAssetsDisclosureTextBlock_zQzLLlWRyPEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 7 &#x2013; &lt;span id="xdx_821_zmrKkgwVOkb5"&gt;OTHER ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zIOw35Jux5Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zbRIZQdcReS7"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zZgu1LSanJT7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Cost"&gt;1,219,657&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zEXMvCqiyBZ3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Accumulated Amortization"&gt;276,720&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_ziLCwYYhutpl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net"&gt;942,937&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTcfQpOLPo36" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zZzx08JOQi06" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;82,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zoO7rjwpWfn2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,031&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930_zySBPLoRjOoc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,303,402&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930_zyTllfP8Io33" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;359,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930_zAyJpsE6jAnj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;943,968&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zxmxTzhFDFg4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,131,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zoYazFQAczwf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;238,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zAVpAGyZtlAl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;892,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zD9Y1ACMIsZi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIv5ay2gjTU3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;78,989&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIjKWkYXHIq8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,756&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIA_c20201231_zXSAhog0vy66" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,215,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIA_c20201231_zHmlHjXOMyH3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;317,614&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtIA_c20201231_z6DP0Cdei4nk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;897,712&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zdv9TzoEDdta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zsPtLVaRUFRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zcGQ6Wze3wkj"&gt;Other assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zVajYRwsRGbl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Cost"&gt;1,352,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zBurs7vt9Wv3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Accumulated Amortization"&gt;1,271,603&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zppYFYdbMGx5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net"&gt;80,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zo7D2BF7uWLk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zRM90gQjpQgd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;165,300&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zLxQSlams8Qg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;84,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Security deposit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zH9PsjF5BiP4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zfEBFhHwd79c" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsNoncurrentGross_iI_c20210930_z3YNithNBji3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,648,165&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930_z2affLAKycqe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,436,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930_zD5pENLuUIw7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211,262&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_z2LURjQh9Um4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,292,729&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zWnXx3HflJcb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,238,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zUyDGPBUHDD7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;54,002&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zmGqnoOi0za4" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsAccumulatedAmortization_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zA1lfyD11R9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,004&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zaQqmKPcXth1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;96,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Security deposit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zc2frW8Xv7uh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zXnX9yBMgyz2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_maOA_c20201231_zuVG0QsOjB6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,588,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_msOA_c20201231_z4aq11NYg4z7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,391,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOA_c20201231_zDZnPTNvJUX2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;197,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zmWJcuRs8psa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zIOw35Jux5Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zbRIZQdcReS7"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zZgu1LSanJT7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Cost"&gt;1,219,657&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zEXMvCqiyBZ3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Accumulated Amortization"&gt;276,720&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_ziLCwYYhutpl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net"&gt;942,937&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTcfQpOLPo36" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zZzx08JOQi06" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;82,714&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zoO7rjwpWfn2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,031&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20210930_zySBPLoRjOoc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,303,402&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210930_zyTllfP8Io33" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;359,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20210930_zAyJpsE6jAnj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;943,968&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zxmxTzhFDFg4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,131,581&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zoYazFQAczwf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;238,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zAVpAGyZtlAl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;892,956&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zD9Y1ACMIsZi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIv5ay2gjTU3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;78,989&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIjKWkYXHIq8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,756&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIA_c20201231_zXSAhog0vy66" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,215,326&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIA_c20201231_zHmlHjXOMyH3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;317,614&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtIA_c20201231_z6DP0Cdei4nk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;897,712&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-09-30_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">1219657</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-09-30_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">276720</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-09-30_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">942937</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-09-30_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">83745</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-09-30_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">82714</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-09-30_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">1031</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1303402</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">359434</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">943968</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">1131581</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">238625</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">892956</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">83745</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">78989</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">4756</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1215326</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">317614</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">897712</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zsPtLVaRUFRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zcGQ6Wze3wkj"&gt;Other assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zVajYRwsRGbl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Cost"&gt;1,352,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zBurs7vt9Wv3" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Accumulated Amortization"&gt;1,271,603&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zppYFYdbMGx5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net"&gt;80,438&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zo7D2BF7uWLk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zRM90gQjpQgd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;165,300&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zLxQSlams8Qg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;84,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Security deposit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherAssetsNoncurrentGross_iI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zH9PsjF5BiP4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zfEBFhHwd79c" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsNoncurrentGross_iI_c20210930_z3YNithNBji3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,648,165&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_c20210930_z2affLAKycqe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,436,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20210930_zD5pENLuUIw7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211,262&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Accumulated
    Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify; padding-left: 0pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_z2LURjQh9Um4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,292,729&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zWnXx3HflJcb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,238,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zUyDGPBUHDD7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;54,002&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zmGqnoOi0za4" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsAccumulatedAmortization_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zA1lfyD11R9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,004&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zaQqmKPcXth1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;96,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Security deposit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsNoncurrentGross_iI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zc2frW8Xv7uh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20201231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zXnX9yBMgyz2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_maOA_c20201231_zuVG0QsOjB6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,588,852&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_msOA_c20201231_z4aq11NYg4z7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,391,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOA_c20201231_zDZnPTNvJUX2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;197,121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-09-30_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1352041</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-09-30_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1271603</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-09-30_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">80438</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-09-30_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">250000</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-09-30_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">165300</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-09-30_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">84700</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-09-30_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</crvw:OtherAssetsNoncurrentGross>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-09-30_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1648165</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1436903</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">211262</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2020-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1292729</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1238727</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2020-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">54002</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2020-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">249999</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">153004</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2020-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">96995</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2020-12-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</crvw:OtherAssetsNoncurrentGross>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2020-12-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1588852</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1391731</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">197121</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_806_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zWwuBQARJPJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 8 &#x2013; &lt;span id="xdx_827_zzg4J29zBTOa"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRrcE2cYYn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_z4FGOvZXvpOh"&gt;Other current liabilities consist of the following&lt;/span&gt;:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210930_z997tbipkYZ2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zFBl1Cothw9i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zx4dXNPeqUwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: justify; padding-left: 0pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;9,172,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;6,843,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedInterestRelatedParties_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_z31DuSbe1Qk2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Accrued interest, related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;230,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AllowanceSystemRemovalCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zIWs6oEWA3Qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Allowance for system removal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,568&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;36,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedVacationCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_z5ltEfshE8b7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Accrued paid time off&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;149,087&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;146,342&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredOfficerCompensation_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zSySN6XQaASf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred officer compensation&lt;sup id="xdx_F42_zjyTxsSyRXje"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zOyqhq7ieJZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Deferred revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;772,730&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;465,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zFkhXP0K8v26" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Insurance premium financing&lt;sup id="xdx_F4A_zwIwak2xDBsj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214,357&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;67,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zy6fp27wxnEl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,514&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzbnp_zUDsNzIIORBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,714,735&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,858,480&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 85%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 80pt"&gt;&#160;&lt;/td&gt;
               &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                          &lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;sup id="xdx_F06_zLsMr6cI2C3f"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td colspan="2" id="xdx_F19_zh0HxeorSdDl"&gt;Salary for Steve Johnson, CEO, between February 15, 2018, and September 30, 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 85%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;sup id="xdx_F0D_zinv0Rro3dqh"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td id="xdx_F18_zVhgFPFiELOb"&gt;Renewal of directors and officer&#x2019;s insurance.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AD_z4IEQ6RjLzs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRrcE2cYYn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_z4FGOvZXvpOh"&gt;Other current liabilities consist of the following&lt;/span&gt;:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210930_z997tbipkYZ2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;September
    30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zFBl1Cothw9i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;December
    31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zx4dXNPeqUwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: justify; padding-left: 0pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;9,172,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;6,843,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedInterestRelatedParties_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_z31DuSbe1Qk2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Accrued interest, related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;230,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AllowanceSystemRemovalCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zIWs6oEWA3Qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Allowance for system removal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27,568&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;36,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedVacationCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_z5ltEfshE8b7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Accrued paid time off&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;149,087&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;146,342&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredOfficerCompensation_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zSySN6XQaASf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred officer compensation&lt;sup id="xdx_F42_zjyTxsSyRXje"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zOyqhq7ieJZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Deferred revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;772,730&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;465,124&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zFkhXP0K8v26" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Insurance premium financing&lt;sup id="xdx_F4A_zwIwak2xDBsj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214,357&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;67,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_zy6fp27wxnEl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,514&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzbnp_zUDsNzIIORBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,714,735&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,858,480&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 85%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 80pt"&gt;&#160;&lt;/td&gt;
               &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                          &lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;sup id="xdx_F06_zLsMr6cI2C3f"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td colspan="2" id="xdx_F19_zh0HxeorSdDl"&gt;Salary for Steve Johnson, CEO, between February 15, 2018, and September 30, 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 85%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18pt"&gt;&lt;sup id="xdx_F0D_zinv0Rro3dqh"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td id="xdx_F18_zVhgFPFiELOb"&gt;Renewal of directors and officer&#x2019;s insurance.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9172557</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6843290</us-gaap:InterestPayableCurrent>
    <crvw:AccruedInterestRelatedParties contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">230136</crvw:AccruedInterestRelatedParties>
    <crvw:AccruedInterestRelatedParties contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">129742</crvw:AccruedInterestRelatedParties>
    <crvw:AllowanceSystemRemovalCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">27568</crvw:AllowanceSystemRemovalCurrent>
    <crvw:AllowanceSystemRemovalCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">36500</crvw:AllowanceSystemRemovalCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">149087</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">146342</us-gaap:AccruedVacationCurrent>
    <crvw:DeferredOfficerCompensation
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="Fact000859"
      unitRef="USD">139041</crvw:DeferredOfficerCompensation>
    <crvw:DeferredOfficerCompensation
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000860"
      unitRef="USD">139041</crvw:DeferredOfficerCompensation>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">772730</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">465124</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="Fact000865"
      unitRef="USD">214357</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000866"
      unitRef="USD">67927</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9259</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">30514</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10714735</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7858480</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z9JRtBOau2Me" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 9 &#x2013;&lt;span id="xdx_82D_z3hT340ARLy1"&gt; INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities are
determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted
tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal
or state income tax for 2021 because of the losses recorded during the nine months ended September 30, 2021, and net operating loss carry
forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201c;more
likely than not&#x201d; that some component or all the benefits of deferred tax assets will not be realized. As of September 30, 2021,
we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income
taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effective tax rate for the nine months ended
September 30, 2021, was different from the federal statutory rate due primarily to change in the valuation allowance and nondeductible
interest and amortization expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 27, 2020, H.R. 748, the Coronavirus Aid,
Relief, and Economic Security Act, &#x201c;the CARES Act,&#x201d; was signed into legislation which includes tax provisions relevant to
businesses that will impact taxes related to 2018, 2019, and 2020. Some of the significant tax law changes are to increase the limitation
on deductible business interest expenses for 2019 and 2020, allow for the five-year carryback of net operating losses for 2018-2020, suspend
the &lt;span id="xdx_90E_ecustom--PercentageOfOperatingLossCarryforwardsLimitationSuspended_iI_dp_c20200327__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zWZ74rkYN8J7"&gt;80&lt;/span&gt;% limitation of taxable income for net operating, loss carryforwards for 2018-2020, provide for the acceleration of depreciation
expense from 2018 and forward on qualified improvement property, and accelerate the ability to claim refunds of AMT credit carryforwards.
The Company is required to recognize the effect on the consolidated financial statements in the period the law was enacted. However, these
changes have no significant impact to the Company due to the loss position and full valuation allowance.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <crvw:PercentageOfOperatingLossCarryforwardsLimitationSuspended
      contextRef="AsOf2020-03-27_us-gaap_InternalRevenueServiceIRSMember"
      decimals="INF"
      unitRef="Pure">0.80</crvw:PercentageOfOperatingLossCarryforwardsLimitationSuspended>
    <crvw:AgreementWithPdlBiopharmaTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_809_ecustom--AgreementWithPdlBiopharmaTextBlock_zKQUQ8m4YtPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 10 &#x2013; &lt;span id="xdx_82C_z4Xd8KZAy7z8"&gt;AGREEMENT WITH PDL BIOPHARMA,
INC.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 26, 2015, we entered into a Credit Agreement
(as subsequently amended) with PDL BioPharma, Inc. (&#x201c;PDL&#x201d;), as administrative agent and lender (&#x201c;the Lender&#x201d;)
(the &#x201c;PDL Credit Agreement&#x201d;). Under the PDL Credit Agreement the Lender made available to us up to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pp0n6_c20150626__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember_z78Vi4HQAR9a" title="Amount available under credit agreement"&gt;40&lt;/span&gt; million in two tranches
of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pp0n6_c20150626__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zTKPDt9V2PR1"&gt;20&lt;/span&gt; million each. Tranche One was funded on October 8, 2015 (the &#x201c;Tranche One Loan&#x201d;). Pursuant to the terms of the PDL
Credit Agreement and having not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding was terminated in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;








&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From October 8, 2015, through May 14, 2019, the
outstanding borrowings under the Tranche One Loan bore interest at the rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20151008__20190513__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_z3B8RJqxjwXk" title="Interest rate during period"&gt;13.5&lt;/span&gt;% per annum, payable quarterly. On May 15, 2019, pursuant
to the terms of the Fifth Amendment to the PDL Credit Agreement (see below for additional details), the interest increased to &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zt0XWIFWX5i9" title="Interest rate"&gt;15.5&lt;/span&gt;% per
annum, payable quarterly. Also, on May 15, 2019, pursuant to the terms of the Fourteenth Amendment to the PDL Modification Agreement (see
below for additional details), the minimum cash balance requirement of $&lt;span id="xdx_90A_ecustom--MinimumCashBalanceRequiredBeforeModification_iI_pp0p0_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zo67OE55Y9y9" title="Minimum cash balance required before modification"&gt;750,000&lt;/span&gt; was reduced to $&lt;span id="xdx_906_eus-gaap--CompensatingBalanceAmount_iI_pp0p0_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zJnmMuc9cajf" title="Minimum cash balance required"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 31, 2019, February 28, 2019, March
29, 2019 and April 29, 2019, the Company and Lender entered into the Tenth, Eleventh, Twelfth, and Thirteenth Amendments to the PDL Modification
Agreement, as previously amended, respectively, pursuant to which the parties agreed to amend the PDL Modification Agreement to provide
that (A) the dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be
July 31, 2018 and, pursuant to the Thirteenth Amendment to the PDL Modification Agreement, May 15, 2019 (rather than January 31, February
28, June 30, and April 30, respectively) (with each such date permitted to be extended by the Lender in its sole discretion); (B) the
Company could satisfy its obligations under the PDL Modification Agreement, as amended, to obtain financing by obtaining (a) at least
$&lt;span id="xdx_907_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190130__20190131__us-gaap--CreditFacilityAxis__custom--TenthPDLModificationAgreementMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__us-gaap--DebtInstrumentRedemptionPeriodOneMember_zVhAXzudFJQj" title="Net cash proceeds for issuance capital stock or debt"&gt;2,050,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to February
23, 2018 and (b) an additional (i) $&lt;span id="xdx_901_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20180227__20180228__us-gaap--CreditFacilityAxis__custom--EleventhPDLModificationAgreementMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__us-gaap--DebtInstrumentRedemptionPeriodTwoMember_zRDMxoB3Twjj" title="Net cash proceeds for issuance capital stock or debt"&gt;750,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock)
or Debt on or prior to July 13, 2018 and (ii) $&lt;span id="xdx_906_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190328__20190329__us-gaap--CreditFacilityAxis__custom--TwelfthPDLModificationAgreementMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__us-gaap--DebtInstrumentRedemptionPeriodFiveMember_zjvB4fiy5a48" title="Net cash proceeds for issuance capital stock or debt"&gt;750,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified
Capital Stock) or Debt on or prior to May 15, 2019 (rather than January 31, February 28, June 30, and April 30, respectively) (resulting
in aggregate net cash proceeds of at least $&lt;span id="xdx_901_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190428__20190429__us-gaap--CreditFacilityAxis__custom--ThirteenPDLModificationAgreementMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__us-gaap--DebtInstrumentRedemptionPeriodFourMember_zLZqMqfioRc9" title="Net cash proceeds for issuance capital stock or debt"&gt;3,550,000&lt;/span&gt;); and (C) the Company&#x2019;s quarterly interest payments that would otherwise have
been due to Lender on December 31, 2018 and June 30, 2019 would be deferred until May 15, 2019 (the end of the extended Modification Period)
and that such deferral would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 9, 2019, the Company, PDL Investment
entered into a Fourth Amendment to PDL Credit Agreement (the &#x201c;Fourth Amendment to the PDL Credit Agreement&#x201d;), wherein the
Company executed an Amended and Restated Tranche One Term Note in the principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20190409__us-gaap--CreditFacilityAxis__custom--FourthAmendmentToThePDLModificationAgreementMember_zgvsHfkXzW29" title="Note amount"&gt;20,000,000&lt;/span&gt; to PDL Investments (the &#x201c;Amended
Tranche One Loan&#x201d;), pursuant to which the parties agreed, among other things, to amend the note from registered to unregistered
form.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 15, 2019, the Company, the Lender, Steven
G. Johnson (our Chief Executive Officer, President, Secretary and Treasurer), individually, and Dr. James R. Higgins (a member of our
board of directors), individually (Mr. Johnson and Dr. Higgins, collectively, the &#x201c;Tranche Three Lenders&#x201d;) entered into a
Fifth Amendment to the PDL Credit Agreement (the &#x201c;Fifth PDL Credit Agreement Amendment&#x201d;), pursuant to which the parties agreed
to amend the PDL Credit Agreement to, among other things, (i) provide for a new tranche of term loan in the aggregate principal amount
of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--MediumTermNotesMember_zQJuQzLobgU3" title="Note amount"&gt;200,000&lt;/span&gt;, from the Tranche Three Lenders, with a maturity date of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--MediumTermNotesMember_z1ruCgCdYvgb" title="Maturity date"&gt;October 7, 2020&lt;/span&gt; and bearing interest at the rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember_zUBKJafLcENk" title="Interest rate"&gt;15.5&lt;/span&gt;% per annum,
payable quarterly in arrears (subject to the terms of the PDL Modification Agreement, as amended) (the &#x201c;Tranche Three Loan&#x201d;);
(ii) increase the interest rate for outstanding borrowings under the Amended Tranche One Loan from &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20151008__20190513__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_z1pOoIbtVlue"&gt;13.5&lt;/span&gt;% per annum to &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zeTwskpgvZNd"&gt;15.5&lt;/span&gt;% per annum,
payable quarterly in arrears (subject to the terms of the PDL Modification Agreement, as amended), effective May 15, 2019,; and (iii)
provide for the issuance of the Twelfth Amendment Note, pursuant to the terms of the Twelfth Amendment to the HealthCor Agreement (see
NOTE 11 for details). Under the accounting standards, we determined that the restructuring of the Tranche One Loan resulted in a troubled
debt restructuring. As the future cash flows were greater than the carrying amount of the debt at the date of the amendment, we accounted
for the change prospectively using the new effective interest rate. Also on May 15, 2019, upon the execution of the Fifth PDL Credit Agreement
Amendment, (i) the Company sold and issued the Tranche Three Lenders term notes in the aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheThreeLoansMember_ziJeZtOh8B47" title="Note amount"&gt;200,000&lt;/span&gt;, payable
in accordance with the terms of the PDL Credit Agreement (the &#x201c;Tranche Three Loans&#x201d;), $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotes4Member__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrJohnsonMember_z1j8658YdALk" title="Note amount"&gt;150,000&lt;/span&gt; from Mr. Johnson and $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotes4Member__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHigginsMember_zb2Toxgb4uGg" title="Note amount"&gt;50,000&lt;/span&gt;
from Dr. Higgins, and (ii) the Company issued a warrant for the purchase of &lt;span id="xdx_901_ecustom--IssuanceOfWarrants_pii_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheThreeLoansMember_zLluM7qDcAch" title="Issuance of warrants"&gt;250,000&lt;/span&gt; shares of Common Stock, with an exercise price per
share equal to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheThreeLoansMember_zdFfDCLFVNig" title="Warrant exercise price (in dollars per share)"&gt;0.03&lt;/span&gt; (subject to adjustment as described therein) and an expiration date of &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20190515__us-gaap--CreditFacilityAxis__custom--FifthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheThreeLoansMember_z337y5wy9yf5" title="Warrant expiration date"&gt;May 15, 2029&lt;/span&gt; (the &#x201c;Tranche Three Loan
Warrant&#x201d;), to Dr. Higgins in connection with his Tranche Three Loan. Mr. Johnson declined to be issued a Tranche Three Loan Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 15, 2019 the Company and the Lender entered
into the Fourteenth Amendment to the PDL Modification Agreement (the &#x201c;Fourteenth Amendment to the PDL Modification Agreement&#x201d;),
pursuant to which, in connection with the Twelfth Amendment to the HealthCor Purchase Agreement (see NOTE 10 for further details) and
the Fifth Amendment to the PDL Credit Agreement, the parties agreed to amend the PDL Modification Agreement, as previously amended, to
provide that (A) the dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period
would be July 31, 2018 and September 30, 2019 (with each such date permitted to be extended by the Lender in its sole discretion); (B)
the Borrower could satisfy its obligations under the PDL Modification Agreement, as amended, to obtain financing by obtaining (a) at least
$&lt;span id="xdx_908_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember__custom--TerminationDateAxis__custom--TerminationDate6Member_zIW3t5YjVYwl" title="Net cash proceeds for issuance capital stock or debt"&gt;2,050,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to February
23, 2018 and (b) an additional (i) $&lt;span id="xdx_900_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember__custom--TerminationDateAxis__custom--TerminationDate5Member_zlcs1GukJv1a" title="Net cash proceeds for issuance capital stock or debt"&gt;1,000,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital
Stock) or Debt on or prior to July 13, 2018 and (ii) $&lt;span id="xdx_902_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember__custom--TerminationDateAxis__custom--TerminationDate4Member_zrXcdRTUW7o2" title="Net cash proceeds for issuance capital stock or debt"&gt;250,000&lt;/span&gt; in net cash proceeds from the issuance of Capital Stock (other than Disqualified
Capital Stock) or Debt on or prior to May 15, 2019 (resulting in aggregate net cash proceeds of at least $&lt;span id="xdx_904_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember__custom--TerminationDateAxis__custom--TerminationDate7Member_zB4BdXG8lNy8" title="Net cash proceeds for issuance capital stock or debt"&gt;3,300,000&lt;/span&gt;); (C) the Liquidity
required during the Modification Period would be lowered to $&lt;span id="xdx_903_ecustom--LiquidityRequiredDuringModificationPeriod_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember_zzN2GU3mcYz8" title="Liquidity required during modification period"&gt;0&lt;/span&gt; from $&lt;span id="xdx_901_ecustom--LiquidityRequiredDuringModificationPeriodBeforeModification_c20190514__20190515__us-gaap--CreditFacilityAxis__custom--FourteenthAmendmentToThePDLModificationAgreementMember_z1ULnTdsMxP5" title="Liquidity required during modification period before modification"&gt;750,000&lt;/span&gt;; and (D) the Company&#x2019;s interest payments that would
otherwise be due to Lender on December 31, 2018, June 30, 2019 and June 30, 2019 would be deferred until September 30, 2019 (the end of
the extended Modification Period) and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2019, the Company, the Borrower,
the Subsidiary Guarantor and the Lender entered into a Fifteenth Amendment to Modification Agreement (the &#x201c;Fifteenth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and November
30, 2019 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s interest payments
that would otherwise be due to Lender on December 31, 2018, June 30, 2019, June 30, 2019, and September 30, 2019 would be deferred until
November 30, 2019 (the end of the extended Modification Period) and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 29, 2019, the Company, the Borrower,
the Subsidiary Guarantor and the Lender entered into a Sixteenth Amendment to Modification Agreement (the &#x201c;Sixteenth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and December
31, 2019 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s interest payments
that would otherwise be due to Lender on December 31, 2018, June 30, 2019, June 30, 2019, and September 30, 2019 would be deferred until
December 31, 2019 (the end of the extended Modification Period) and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 31, 2019, the Company, the Borrower,
the Subsidiary Guarantor and the Lender entered into a Seventeenth Amendment to Modification Agreement (the &#x201c;Seventeenth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and January 17,
2020 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s interest payments
that would otherwise be due to Lender on December 31, 2018, June 30, 2019, June 30, 2019, September 30, 2019, and December 31, 2019 would
be deferred until January 17, 2020 (the end of the extended Modification Period) and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 17, 2020, the Company, the Borrower,
the Subsidiary Guarantor and the Lender entered into an Eighteenth Amendment to Modification Agreement (the &#x201c;Eighteenth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and January 28,
2020 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s interest payments
that would otherwise be due to Lender on December 31, 2018, June 30, 2019, June 30, 2019, September 30, 2019, and December 31, 2019 would
be deferred until January 28, 2020 (the end of the extended Modification Period) and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 28, 2020, the Company, the Borrower,
the Subsidiary Guarantor and the Lender entered into a Nineteenth Amendment to Modification Agreement (the &#x201c;Nineteenth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and (i) April
30, 2020 (provided that Borrower obtains at least $&lt;span id="xdx_90C_ecustom--NetCashProceedsForIssuanceCapitalStockOrDebt_c20200127__20200128__us-gaap--CreditFacilityAxis__custom--NineteenthAmendmentToThePDLModificationAgreementMember_zQ1Xck3v0yfe"&gt;600,000&lt;/span&gt; in cash proceeds from the issuance of Capital Stock (other than Disqualified
Capital Stock) or Debt subordinated to the Tranche One Loan (as defined in the Credit Agreement) pursuant to the terms of the Intercreditor
Agreement (as defined in the Credit Agreement) on or prior to February 11, 2020) or (ii) February 11, 2020 (if Borrower has not obtained
such cash proceeds by such date) (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s
interest payments that would otherwise be due to Lender on December 31, 2018, June 30, 2019, June 30, 2019, September 30, 2019, December
31, 2019, and June 30, 2020 would be deferred until the end of the extended Modification Period (but with respect to the June 30, 2020
interest payment, such payment would be deferred only in the event that the end of the extended Modification Period is April 30, 2020
rather than February 11, 2020; otherwise the Borrower will make the interest payment due under the Credit Agreement on June 30, 2020),
and that such deferrals would be a Covered Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated the Eighteenth and Nineteenth
Modification Agreement Amendments and as the effective borrowing rate under the restructured agreement is less than the effective borrowing
rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement
was accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 6, 2020, the Company, the Borrower,
the Lender (in its capacity as administrative agent and lender) and the Tranche Three Lenders entered into a Sixth Amendment to Credit
Agreement (the &#x201c;Sixth Credit Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Credit Agreement to,
among other things, (i) provide for additional funding under the Tranche Three Loan, in the aggregate principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--MediumTermNotesMember_zCx2H66fQ705" title="Note amount"&gt;500,000&lt;/span&gt;, from
the Tranche Three Lenders (the &#x201c;Additional Tranche Three Loan&#x201d;), with a maturity date of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200205__20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--MediumTermNotesMember_zzcqy2fGr578" title="Maturity date"&gt;October 7, 2020&lt;/span&gt; (the fifth anniversary
of the funding date of the Tranche One Loan (as defined in the Credit Agreement)), with outstanding borrowings bearing interest at the
rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--MediumTermNotesMember_zvogDSg5ZlBg" title="Interest rate"&gt;15.5&lt;/span&gt;% per annum, payable quarterly in arrears (subject to the terms of the Modification Agreement, as amended), and with payment
of the Additional Tranche Three Loan and any other Obligations (as defined in the Credit Agreement) incurred in connection with the Additional
Tranche Three Loan subordinated and subject in right and time of payment to the Payment in Full (as defined in the Credit Agreement) of
the Tranche One Loan and any other Obligations incurred in connection with the Tranche One Loan, to the extent and in the manner set forth
in the Credit Agreement; and (ii) provide for the issuance of the Thirteenth Amendment Supplemental Closing Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also on February 6, 2020, upon the execution of
the Sixth Credit Agreement Amendment, (i) the Borrower borrowed the Additional Tranche Three Loan and issued to the Tranche Three Lenders
term notes in the aggregate principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember_zAYWq0AInCKh" title="Note amount"&gt;500,000&lt;/span&gt;, payable in accordance with the terms of the Credit Agreement (the &#x201c;Additional
Tranche Three Term Notes&#x201d;), $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrJohnsonMember_zns8TxRMnas7" title="Note amount"&gt;250,000&lt;/span&gt; from Mr. Johnson and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHigginsMember_z8NZFWThwNc3"&gt;250,000&lt;/span&gt; from Dr. Higgins, and (ii) the Company issued a warrant for the
purchase of &lt;span id="xdx_900_ecustom--IssuanceOfWarrants_pii_c20200205__20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHigginsMember_zNBLmiPEtAK9" title="Issuance of warrants"&gt;1,000,000&lt;/span&gt; shares of Common Stock, with an exercise price per share equal to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHigginsMember_z28Cgy0rKTWf" title="Warrant exercise price (in dollars per share)"&gt;0.01&lt;/span&gt; (subject to adjustment as described therein)
and expiration date of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20200206__us-gaap--CreditFacilityAxis__custom--SixthPDLCreditAgreementAmendmentMember__us-gaap--LongtermDebtTypeAxis__custom--MediumTermNotesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHigginsMember_zOXICwYD9Vba" title="Warrant expiration date"&gt;February 6, 2030&lt;/span&gt; (the &#x201c;Additional Tranche Three Loan Warrant&#x201d;), to Dr. Higgins in connection with his
Additional Tranche Three Loan. Mr. Johnson declined to be issued an Additional Tranche Three Loan Warrant. Mr. Johnson is our Chief Executive
Officer, President, Secretary and Treasurer and is one of our directors. Dr. Higgins is one of our directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2020, the Company and PDL Investment
Holdings, LLC, entered into a Consent and Agreement Regarding SBA Loan Agreement (the &#x201c;PDL Consent Agreement&#x201d;), pursuant to
which the Lender (i) consented under the Credit Agreement to the Borrower&#x2019;s issuing the Promissory Note and borrowing the SBA Loan
and (ii) agreed that the SBA Loan would be deemed to be debt that is permitted under the Credit Agreement and Loan Documents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2020, the Company and the Lender
entered into a Twentieth Amendment to the PDL Modification Agreement (the &#x201c;Twentieth Modification Agreement Amendment&#x201d;), pursuant
to which the parties agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender&#x2019;s
sole discretion, to terminate the Modification Period would be July 31, 2018 and September 30, 2020 (with each such date permitted to
be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s interest payments that would otherwise be due to Lender
on December 31, 2018, June 30, 2019, June 30, 2019, September 30, 2019, December 31, 2019, June 30, 2020 and June 30, 2020 would be deferred
until September 30, 2020 (the end of the extended Modification Period), and that such deferrals would be a Covered Event. The Company
has evaluated the Twentieth Modification Agreement Amendment and as the effective borrowing rate under the restructured agreement is less
than the effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession
has been granted, the agreement was accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2020, the Company, the Borrower,
the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-First Amendment to Modification Agreement (the
&#x201c;Twenty- First Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement
to provide that the dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would
be July 31, 2018 and November 30, 2020 (with each such date permitted to be extended by the Lender in its sole discretion); and that the
Borrower&#x2019;s (i) interest payments that would otherwise be due under the Credit Agreement on December 31, 2018, March 31, 2019, June
30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020 and October 7, 2020 and (ii) payments
for principal and for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three Loans that would otherwise
be due under the Credit Agreement on October 7, 2020, would each be deferred until November 30, 2020 (the end of the extended Modification
Period), and that such deferrals would be a Covered Event. The Company has evaluated the Twenty-First Modification Agreement Amendment
and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on the old agreement, a
concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement was accounted for as
a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 30, 2020, the Company, the Borrower,
the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Second Amendment to Modification Agreement (the
&#x201c;Twenty-Second Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement
to provide that the dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would
be July 31, 2018 and January 31, 2021 (with each such date permitted to be extended by the Lender in its sole discretion); and that the
Borrower&#x2019;s (i) interest payments that would otherwise be due under the Credit Agreement on December 31, 2018, March 31, 2019, June
30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020, and October 7, 2020 and (ii) payments
for principal and for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three Loans that would otherwise
be due under the Credit Agreement on October 7, 2020, would each be deferred until January 31, 2021 (the end of the extended Modification
Period) and that such deferrals would be a Covered Event. The Company has evaluated the Twenty-Second Modification Agreement Amendment
and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on the old agreement, a
concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement was accounted for as
a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 31, 2021, the Company, the Borrower,
the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Third Amendment to Modification Agreement (the
&#x201c;Twenty-Third Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement
to provide that the dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would
be July 31, 2018 and January 31, 2021 (with each such date permitted to be extended by the Lender in its sole discretion); and that the
Borrower&#x2019;s (i) interest payments that would otherwise be due under the Credit Agreement on December 31, 2018, March 31, 2019, June
30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020, and October 7, 2020 and (ii) payments
for principal and for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three Loans that would otherwise
be due under the Credit Agreement on October 7, 2020, would each be deferred until May 31, 2021 (the end of the extended Modification
Period) and that such deferrals would be a Covered Event. The Company has evaluated the Twenty-Third Modification Agreement Amendment
and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on the old agreement, a
concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement was accounted for as
a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 25, 2021, the Company, the Borrower, the
Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Fourth Amendment to Modification Agreement (the &#x201c;Twenty-Fourth
Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the
dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July&#160;31,
2018 and November 30, 2021 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s
(i)&#160;interest payments that would otherwise be due under the Credit Agreement on December&#160;31, 2018, March&#160;31, 2019, June&#160;30,
2019, September&#160;30, 2019, December&#160;31, 2019, March&#160;31, 2020, June&#160;30, 2020, September&#160;30, 2020, October&#160;7,
2020, and (ii)&#160;payments for principal and for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three
Loans that would otherwise be due under the Credit Agreement on October&#160;7, 2020, would each be deferred until November 30, 2021 (the
end of the extended Modification) and that such deferrals would be a Covered Event. The Company has evaluated the Twenty-Fourth Modification
Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on
the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement
is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Accounting Treatment &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the PDL Credit Agreement, as
amended, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $&lt;span id="xdx_902_ecustom--DeferredIssuanceCosts_iI_c20210930__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantPurchaseAgreementMember_z3e7ACKkWed8" title="Deferred issuance costs"&gt;1,600,000&lt;/span&gt; which has been recorded
as deferred issuance costs in the accompanying consolidated financial statements. As of September 30, 2021, the Amended PDL Warrant has
not been exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, the Company and Lender
had entered into twenty-four amendments to the PDL Modification Agreement (as detailed above), resulting in restructuring of the PDL Credit
Agreement and the accounting treatment of the related costs. Under debt modification/troubled debt guidance, we determined that the first
of the eight amendments had no cash flow impact, and therefore, had no impact on accounting. Amendments nine through ten qualified for
modification accounting, while the final fourteen amendments qualified for troubled debt restructuring accounting. As appropriate, we
expensed the legal costs paid to third parties. For the nine months ended September 30, 2021, and 2020, pursuant to the terms of the PDL
Modification Agreement, as amended, $&lt;span id="xdx_90F_eus-gaap--InterestExpense_pp0p0_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PDLModificationAgreementMember_zyEsxQFLwNr9" title="Interest Expense"&gt;2,325,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--PDLModificationAgreementMember_z8iGdO6ZFBwe" title="Interest Expense"&gt;2,325,000&lt;/span&gt;, respectively, was recorded as interest expense on the accompanying consolidated
financial statements.&lt;/p&gt;

</crvw:AgreementWithPdlBiopharmaTextBlock>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2015-06-26_custom_PDLBioPharmaIncMember"
      decimals="0"
      unitRef="USD">40000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2015-06-26_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2015-10-082019-05-13_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.135</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.155</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <crvw:MinimumCashBalanceRequiredBeforeModification
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">750000</crvw:MinimumCashBalanceRequiredBeforeModification>
    <us-gaap:CompensatingBalanceAmount
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">0</us-gaap:CompensatingBalanceAmount>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-01-302019-01-31_custom_TenthPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodOneMember"
      decimals="0"
      unitRef="USD">2050000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2018-02-272018-02-28_custom_EleventhPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodTwoMember"
      decimals="0"
      unitRef="USD">750000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-03-282019-03-29_custom_TwelfthPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodFiveMember"
      decimals="0"
      unitRef="USD">750000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-04-282019-04-29_custom_ThirteenPDLModificationAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodFourMember"
      decimals="0"
      unitRef="USD">3550000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-04-09_custom_FourthAmendmentToThePDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-05-142019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">2020-10-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember"
      decimals="INF"
      unitRef="Pure">0.155</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2015-10-082019-05-13_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.135</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.155</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_MediumTermNotes4Member_custom_MrJohnsonMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_MediumTermNotes4Member_custom_DrHigginsMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <crvw:IssuanceOfWarrants
      contextRef="From2019-05-142019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember"
      decimals="INF"
      unitRef="Shares">250000</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember"
      decimals="INF"
      unitRef="USDPShares">0.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2019-05-15_custom_FifthPDLCreditAgreementAmendmentMember_custom_TrancheThreeLoansMember">2029-05-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate6Member"
      decimals="0"
      unitRef="USD">2050000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate5Member"
      decimals="0"
      unitRef="USD">1000000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate4Member"
      decimals="0"
      unitRef="USD">250000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember_custom_TerminationDate7Member"
      decimals="0"
      unitRef="USD">3300000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <crvw:LiquidityRequiredDuringModificationPeriod
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">0</crvw:LiquidityRequiredDuringModificationPeriod>
    <crvw:LiquidityRequiredDuringModificationPeriodBeforeModification
      contextRef="From2019-05-142019-05-15_custom_FourteenthAmendmentToThePDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">750000</crvw:LiquidityRequiredDuringModificationPeriodBeforeModification>
    <crvw:NetCashProceedsForIssuanceCapitalStockOrDebt
      contextRef="From2020-01-272020-01-28_custom_NineteenthAmendmentToThePDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">600000</crvw:NetCashProceedsForIssuanceCapitalStockOrDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-02-052020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember">2020-10-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_us-gaap_MediumTermNotesMember"
      decimals="INF"
      unitRef="Pure">0.155</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_MrJohnsonMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <crvw:IssuanceOfWarrants
      contextRef="From2020-02-052020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember"
      decimals="INF"
      unitRef="Shares">1000000</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-02-06_custom_SixthPDLCreditAgreementAmendmentMember_custom_MediumTermNotesOneMember_custom_DrHigginsMember">2030-02-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <crvw:DeferredIssuanceCosts
      contextRef="AsOf2021-09-30_custom_PDLBioPharmaIncMember_custom_WarrantPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">1600000</crvw:DeferredIssuanceCosts>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-09-30_custom_PDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">2325000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-09-30_custom_PDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">2325000</us-gaap:InterestExpense>
    <crvw:AgreementWithHealthcorTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80F_ecustom--AgreementWithHealthcorTextBlock_zelXroBc2DX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 11 &#x2013; &lt;span id="xdx_828_zxW8x6Uw2Do5"&gt;AGREEMENT WITH HEALTHCOR&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 21, 2011, we entered into a Note and
Warrant Purchase Agreement (as subsequently amended) with HealthCor Partners Fund, LP (&#x201c;HealthCor Partners&#x201d;) and HealthCor
Hybrid Offshore Master Fund, LP (&#x201c;HealthCor Hybrid&#x201d; and, together with HealthCor Partners, &#x201c;HealthCor&#x201d;) (the &#x201c;HealthCor
Purchase Agreement&#x201d;). Pursuant to the terms of the HealthCor Purchase Agreement, we sold and issued Senior Secured Convertible Notes
to HealthCor in the principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0ptZ5I0qSD1" title="Note amount"&gt;9,316,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt1Member_z9zcFlty56G8"&gt;10,684,000&lt;/span&gt;, respectively (collectively the &#x201c;2011 HealthCor Notes&#x201d;).
The 2011 HealthCor Notes have a maturity date of &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_pid_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZqiN7oTfuA" title="Debt maturity date"&gt;April 20, 2021&lt;/span&gt;. We also issued Warrants to HealthCor for the purchase of an aggregate
of up to &lt;span id="xdx_909_ecustom--IssuanceOfWarrants_pid_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6Aa27CY1k2i" title="Issuance of warrants"&gt;5,488,456&lt;/span&gt; and &lt;span id="xdx_90C_ecustom--IssuanceOfWarrants_pii_uShares_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt1Member_zslNXvJII0S1"&gt;6,294,403&lt;/span&gt; shares, respectively, of our Common Stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zy969ImnC32a" title="Exercise price of warrants"&gt;1.40&lt;/span&gt; per share (collectively the &#x201c;2011
HealthCor Warrants&#x201d;). So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes
accrue interest from April 21, 2011, through April 20, 2016 (the &#x201c;First Five-Year Note Period&#x201d;) at the rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member__us-gaap--VariableRateAxis__custom--FirstFiveYearNotePeriodMember_zy8SpneIG4vg" title="Interest rate"&gt;12.5&lt;/span&gt;% per annum,
compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar
quarter. Interest accruing from April 21, 2016, through April 20, 2021 (the &#x201c;Second Five Year Note Period&#x201d;) at a rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pii_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member__us-gaap--VariableRateAxis__custom--SecondFiveYearNotePeriodMember_z6s25FlkeWk6"&gt;10&lt;/span&gt;%
per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding
principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. For the period from April 21, 2016, through September
30, 2018, interest has been added to the outstanding principal balance. Pursuant to the terms of the Ninth Amendment, the accrual of interest
has been suspended after September 30, 2018. From the date any event of default occurs, the interest rate, then applicable, shall be increased
by five percent (&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member_zJYcttkj2jF" title="Increase in interest rate (per annum) should default occur"&gt;5&lt;/span&gt;%) per annum. HealthCor has the right, upon an event of default, to declare due and payable any unpaid principal amount
of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid interest and charges, together with the interest then
scheduled to accrue (calculated at the default rate described in the immediately preceding sentence) through the end of the First Five
Year Note Period or the Second Five Year Note Period, as applicable. Subject to the terms of the Ninth Amendment as discussed below, HealthCor&#x2019;s
ability to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into
fully paid and nonassessable shares of our Common Stock has been eliminated. The warrants issued with this Note were cancelled with the
Ninth-Amendment dated July 10, 2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 31, 2012, we entered the Second Amendment
to the HealthCor Purchase Agreement with HealthCor (the &#x201c;Second Amendment&#x201d;) amending the HealthCor Purchase Agreement and
sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20120131__srt--CounterpartyNameAxis__custom--HealthCor4Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt4Member_zj2Hjtrm26tj"&gt;2,329,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20120131__srt--CounterpartyNameAxis__custom--HealthCor4Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt5Member_zAyNMf9dzv4f"&gt;2,671,000&lt;/span&gt;, respectively (collectively the
&#x201c;2012 HealthCor Notes&#x201d;). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form
as the 2011 HealthCor Notes, with changes to the &#x201c;Issuance Date,&#x201d; &#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note
Period&#x201d; and other terms to consider the timing of the issuance of the 2012 HealthCor Notes. On April 20, 2021, we entered the Fourteenth
Amendment to Note and Warrant Purchase Agreement (&#x201c;Fourteenth-Amendment&#x201d;) with HealthCor, the 2015 Investors, the February
2018 Investors, the July 2018 Investors, the 2019 Investor, and the February 2020 Investor amending the 2011 HealthCor Notes and 2012
HealthCor Notes.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 16, 2014, we entered a Fourth Amendment
to the HealthCor Purchase Agreement with HealthCor (the &#x201c;Fourth Amendment&#x201d;) and sold Senior Secured Convertible Notes to HealthCor
in the principal amounts of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20140116__srt--CounterpartyNameAxis__custom--HealthCor6Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt7Member_zvZFKvG8omx7"&gt;2,329,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20140116__srt--CounterpartyNameAxis__custom--HealthCor6Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt6Member_znWNssDk0hb6"&gt;2,671,000&lt;/span&gt; (collectively &#x201c;the 2014 HealthCor Notes&#x201d;). As provided by the Fourth
Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the &#x201c;Issuance
Date,&#x201d; &#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note Period&#x201d; and other terms to consider the timing of the issuance
of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20140115__20140116__srt--CounterpartyNameAxis__custom--HealthCor6Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zX8yQFveh1Tj"&gt;January 15, 2024&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 4, 2014, we entered into a Fifth Amendment
to the HealthCor Purchase Agreement (the &#x201c;Fifth Amendment&#x201d;) with HealthCor and certain additional investors (such additional
investors, the &#x201c;2015 Investors&#x201d; and, collectively with HealthCor, the &#x201c;Investors&#x201d;) and agreed to sell and issue
(i) additional notes in the initial aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20141204__srt--CounterpartyNameAxis__custom--HealthCor7Member_zPCxBePrdPp9"&gt;6,000,000&lt;/span&gt;,with a conversion price per share of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20141204__srt--CounterpartyNameAxis__custom--HealthCor7Member_zaEIHkqJV8C9" title="Debt conversion price"&gt;0.52&lt;/span&gt; (subject to adjustment
as described therein) (the &#x201c;Fifth Amendment Notes&#x201d;) and (ii) additional Warrants for an aggregate of up to &lt;span id="xdx_905_ecustom--IssuanceOfWarrants_pii_uShares_c20141203__20141204__srt--CounterpartyNameAxis__custom--HealthCor7Member_zUZI8P66T648"&gt;3,692,308&lt;/span&gt; shares
of our Common Stock at an exercise price per share of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20141204__srt--CounterpartyNameAxis__custom--HealthCor7Member_zsGVq5gguhT8"&gt;0.52&lt;/span&gt; (subject to adjustment as described therein) (the &#x201c;Fifth Amendment Warrants&#x201d;).
As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes
to the &#x201c;Issuance Date,&#x201d; &#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note Period&#x201d; and other terms to consider
the timing of the issuance of the Fifth Amendment Notes. The Fifth Amendment Notes have a maturity date of &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_pii_dd_c20141203__20141204__srt--CounterpartyNameAxis__custom--HealthCor7Member_z0FRNRDKnpY3"&gt;February 16, 2025&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2018, we entered into an Eighth
Amendment to the HealthCor Purchase Agreement (the &#x201c;Eighth Amendment&#x201d;) with HealthCor, the 2015 Investors and certain investors
(such additional investors, the &#x201c;February 2018 Investors&#x201d;) and agreed to sell and issue (i) additional notes in the initial
aggregate principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20180223__srt--CounterpartyNameAxis__custom--HealthCor10Member_ztJjM9z8Wt5h"&gt;2,050,000&lt;/span&gt;,with a conversion price per share of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_uUSDPShares_c20180223__srt--CounterpartyNameAxis__custom--HealthCor10Member_zG9pOwOX7BKk"&gt;0.05&lt;/span&gt; (subject to adjustment as described therein) (the
&#x201c;Eighth Amendment Notes&#x201d;) and (ii) additional Warrants for an aggregate of up to &lt;span id="xdx_90D_ecustom--IssuanceOfWarrants_pid_c20180222__20180223__srt--CounterpartyNameAxis__custom--HealthCor10Member_zSR4fZ2O4gCl"&gt;512,500&lt;/span&gt; shares of our Common Stock at an
exercise price per share of $0.05 (subject to adjustment as described therein) (the &#x201c;Eighth Amendment Warrants&#x201d;). As provided
by the Eighth Amendment, the Eighth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the
&#x201c;Issuance Date,&#x201d; &#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note Period&#x201d; and other terms to consider the timing
of the issuance of the Eighth Amendment Notes. The Eighth Amendment Notes have a maturity date of&lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20180222__20180223__srt--CounterpartyNameAxis__custom--HealthCor10Member_z2P3tTQDm0Jg"&gt; February 22, 2028&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 10, 2018, we entered into the Ninth Amendment
to the HealthCor Purchase Agreement (the &#x201c;Ninth Amendment&#x201d;) with HealthCor, the 2015 Investors and the February 2018 Investors,
pursuant to which the parties agreed to amend the HealthCor Purchase Agreement, the 2011 HealthCor Notes, the 2012 HealthCor Notes, the
2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes, as applicable, to (i) remove the rights of the holders
of the 2011 HealthCor Notes and the 2012 HealthCor Notes to convert such notes to Common Stock after September 30, 2018; (ii) suspend
the accrual of interest on the 2011 HealthCor Notes and the 2012 HealthCor Notes for periods after September 30, 2018; (iii) provide for
the potential earlier repayment of the 2011 HealthCor Notes and the 2012 HealthCor Notes by the Company, 120 calendar days following a
written demand for payment by the holder of such notes; provided, however, that such written demand may not be given prior to the twelve-month
anniversary of the date on which the obligations of the Company under the PDL Credit Agreement are repaid in full; (iv) cancel the 2011
HealthCor Warrants; (v) provide for the seniority of the 2011 HealthCor Notes and the 2012 HealthCor Notes in right of payment over notes
subsequently issued pursuant to the Purchase Agreement, including the 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment
Notes; (vi) amend the terms of the 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes to reflect the seniority
in payment of the 2011 HealthCor Notes and 2012 HealthCor Notes; and (vii) reduce the number of shares of Common Stock that the Company
must at all times have authorized and reserved for the purpose of issuance upon conversion of the notes issued pursuant to the HealthCor
Purchase Agreement (collectively, the &#x201c;Notes&#x201d;) and exercise of the warrants issued pursuant to the HealthCor Purchase Agreement
(collectively, the &#x201c;Warrants&#x201d;), from at least &lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_c20180709__20180710__srt--CounterpartyNameAxis__custom--HealthCorNinthAmedmentPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5BNfapuERce" title="Conversion of notes"&gt;120&lt;/span&gt;% of the aggregate number of shares of Common Stock then issuable upon full
conversion of the Notes and exercise of the Warrants to at least &lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_c20180709__20180710__srt--CounterpartyNameAxis__custom--HealthCorNinthAmedmentPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zwZlD3vuUkb7"&gt;100&lt;/span&gt;% of such aggregate number of shares. In addition, on July 10, 2018,
along with PDL, HealthCor, the 2015 Investors and the February 2018 Investors, we entered into a Second Amendment to the Subordination
and Intercreditor Agreement, to amend the Subordination and Intercreditor Agreement dated as of September 26, 2015, as amended to provide
that, in the event of a sale of the Company&#x2019;s hospital assets, after the net proceeds are first applied to repay obligations under
the PDL Credit Agreement, as amended, until paid in full, up to the next $&lt;span id="xdx_905_ecustom--NetProceedsToBeRetainedFromSaleOfHospitalAssets_dp_c20180709__20180710__srt--CounterpartyNameAxis__custom--HealthCorNinthAmedmentPurchaseAgreementMember_zTYV48YXZmYg" title="Net proceeds to be retained from sale of hospital assets"&gt;5,000,000&lt;/span&gt; of such net proceeds may be retained by the Company
for working capital purposes before all remaining net proceeds are then applied to repay the obligations under the Notes in accordance
with the priorities set forth in the HealthCor Purchase Agreement and the Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 13, 2018, we entered into the Tenth Amendment
to the HealthCor Purchase Agreement with HealthCor, the 2015 Investors, the February 2018 Investors and certain investors (all of which
are directors of the Company) (such additional investors, the &#x201c;July 2018 Investors&#x201d;), pursuant to which we sold and issued
convertible secured promissory notes for an aggregate of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20180713__srt--CounterpartyNameAxis__custom--HealthCorTenthAmendmentMember_zYHOcXhhL1e1"&gt;1,000,000&lt;/span&gt; to the July 2018 Investors with a conversion price per share equal
to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_uUSDPShares_c20180713__srt--CounterpartyNameAxis__custom--HealthCorTenthAmendmentMember_z8MA0QMXOa61"&gt;0.05&lt;/span&gt; (subject to adjustment as described therein) (the &#x201c;Tenth Amendment Notes&#x201d;). As provided by the Tenth Amendment, the
Tenth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the &#x201c;Issuance Date,&#x201d;
&#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note Period&#x201d; and other terms to consider the timing of the issuance of the Tenth
Amendment Notes. The Tenth Amendment Notes have a maturity date of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20180712__20180713__srt--CounterpartyNameAxis__custom--HealthCorTenthAmendmentMember_zfhfWjBB3l37"&gt;July 12, 2028&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 15, 2019, we entered into the Twelfth Amendment
to HealthCor Purchase Agreement with HealthCor, the 2015 Investors, the February 2018 Investors, the July 2018 Investors, and an investor
(a member of our board of directors) (such additional investor, the &#x201c;2019 Investor&#x201d;), pursuant to which we sold and issued
a convertible secured promissory note for $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20190515__srt--CounterpartyNameAxis__custom--HealthCor14Member__srt--TitleOfIndividualAxis__custom--HealthCorNewInvestors1Member_zlKxghocva2i"&gt;50,000&lt;/span&gt; to the 2019 Investor with a conversion price per share equal to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_uUSDPShares_c20190515__srt--CounterpartyNameAxis__custom--HealthCor14Member__srt--TitleOfIndividualAxis__custom--HealthCorNewInvestors1Member_z8WrQZUTlrR4"&gt;0.03&lt;/span&gt; (subject to adjustment
as described therein) (the &#x201c;Twelfth Amendment Note&#x201d;). As provided by the Twelfth Amendment, the Twelfth Amendment Note is
in substantially the same form as the 2011 HealthCor Notes, with changes to the &#x201c;Issuance Date,&#x201d; &#x201c;Maturity Date,&#x201d;
&#x201c;First Five-Year Note Period&#x201d; and other terms to take into account the timing of the issuance of the Twelfth Amendment Note.
The Twelfth Amendment Note has a maturity date of &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20190514__20190515__srt--CounterpartyNameAxis__custom--HealthCor14Member__srt--TitleOfIndividualAxis__custom--HealthCorNewInvestors1Member_zU2g43H7u3O2"&gt;May 15, 2029&lt;/span&gt;. In addition, the provisions regarding interest payments, interest acceleration,
optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the
2011 HealthCor Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 6, 2020, we entered into the Thirteenth
Amendment to HealthCor Purchase Agreement with HealthCor, the 2015 Investors, the February 2018 Investors, the July 2018 Investors, the
2019 Investor and an investor (a member of our board of directors) (such additional investor, the &#x201c;February 2020 Investor&#x201d;),
pursuant to which (i) we sold and issued a convertible secured promissory note for $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20200206__srt--CounterpartyNameAxis__custom--HealthCorThirteenMember__srt--TitleOfIndividualAxis__custom--HealthCorNewInvestorsOne1Member__us-gaap--DebtInstrumentAxis__custom--ThirteenthAmendmentNoteMember_zxcxLBi15JWk"&gt;100,000&lt;/span&gt; to the February 2020 Investor with a conversion
price per share equal to $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20200206__srt--CounterpartyNameAxis__custom--HealthCorThirteenMember__srt--TitleOfIndividualAxis__custom--HealthCorNewInvestorsOne1Member__us-gaap--DebtInstrumentAxis__custom--ThirteenthAmendmentNoteMember_zcuIzexDLS8e"&gt;0.01&lt;/span&gt; (subject to adjustment as described therein) (the &#x201c;Thirteenth Amendment Note&#x201d;). As provided
by the Twelfth Amendment, the Twelfth Amendment Note is in substantially the same form as the 2011 HealthCor Notes, with changes to the
&#x201c;Issuance Date,&#x201d; &#x201c;Maturity Date,&#x201d; &#x201c;First Five-Year Note Period&#x201d; and other terms to consider the timing
of the issuance of the Thirteenth Amendment Note. The Thirteenth Amendment Note has a maturity date of February 5, 2030. In addition,
the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive
rights and registration rights are the same as those of the 2011 HealthCor Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2020, the Company and holders of
at least a majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock, on an as-converted
basis, sold pursuant to the Note and Warrant Purchase Agreement dated April 21, 2011, as amended, by and among HealthCor Partners Fund,
LP, HealthCor Hybrid Offshore Master Fund, LP and the other investors party thereto (the &#x201c;Majority Holders&#x201d;) (the &#x201c;Purchase
Agreement&#x201d;), entered into a Consent and Agreement Regarding SBA Loan Agreement (the &#x201c;NWPA Consent Agreement&#x201d;), pursuant
to which the Majority Holders (i) consented under the Purchase Agreement to the Borrower&#x2019;s issuing the Promissory Note and borrowing
the SBA Loan and (ii) agreed that the SBA Loan would be deemed to be Permitted Indebtedness under the Purchase Agreement (as defined therein).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 20, 2021, we agreed with the HealthCor
Parties to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor Notes from &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20210417__20210418__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_z1ul314qevA"&gt;April 20, 2021&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zbm9ppIoLIN5"&gt;April 20,
2022&lt;/span&gt; by entering into Allonge No. 3 to the 2011 HealthCor Notes (the &#x201c;Third 2011 Note Allonges&#x201d;) and (ii) amend the 2012 HealthCor
Notes to extend the maturity date of the 2012 HealthCor Notes from &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20210417__20210418__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2012Member_zUxNAg1RgCJb"&gt;January 30, 2022&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2012Member_zh9Z25F7Tz3g"&gt;April 20, 2022&lt;/span&gt; by entering into Allonge No. 3 to
the 2012 HealthCor Notes (the &#x201c;Third 2012 Note Allonges&#x201d;) (such amendments to the 2011 HealthCor Notes and 2012 HealthCor
Notes together, the &#x201c;HealthCor Note Extensions&#x201d;). In connection with the HealthCor Note Extensions, we issued warrants to
purchase an aggregate of &lt;span id="xdx_904_ecustom--IssuanceOfWarrants_uShares_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zBhhw3xDkkC1"&gt;2,000,000&lt;/span&gt; shares of our Common Stock at an exercise price per share equal to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_z9t9d0iIseul"&gt;0.23&lt;/span&gt; per share (subject to adjustment
as described therein) and with an expiration date of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zYOIWwwd6Yw6" title="Warrants expiration date"&gt;April 20, 2031&lt;/span&gt;, to the HealthCor Parties (collectively the &#x201c;2021 HealthCor
Warrants&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also on April 20, 2021, in connection with the
HealthCor Note Extensions and the issuance of the 2021 HealthCor Warrants, we entered into a Consent and Agreement Pursuant to Note and
Warrant Purchase Agreement (the &#x201c;2021 NWPA Consent&#x201d;) with the HealthCor Parties and certain additional Existing Investors
(in their capacity as Majority Holders acting together with the HealthCor Parties), pursuant to which, among other things, (i) the Majority
Holders consented to the HealthCor Note Extensions, (ii) the Majority Holders consented to the issuance of the 2021 HealthCor Warrants
and (iii) the parties agreed that the holders of the 2021 HealthCor Warrants would have registration rights for the shares of Common Stock
issuable upon exercise of the 2021 HealthCor Warrants under the Registration Rights Agreement dated as of April 20, 2011, as amended June
30, 2015, by and among the Company, the HealthCor Parties and the additional investors party thereto (the &#x201c;Registration Rights Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock_z0BfPQj3ESul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zeEBCNxO8zT2"&gt;Below is a summary of the total underlying shares
of common stock related to HealthCor and related investors&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -10pt"&gt;&lt;b&gt;Investor Group&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Underlying
    Shares of Common Stock&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify; padding-left: 0pt"&gt;2014 HealthCor Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2014Member_z80vakQwGvc5" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;30,222,101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2015 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2015Member_zv07FfeOQaS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,879,399&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2015 HealthCor Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2015Member_zmcwKoNknX6b" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,175,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;February 2018 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2018InvestorsMember_zlEbi3VzAFe8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,866,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;July 2018 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--July2018InvestorsMember_zqAAd5MCALi6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,709,949&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2019 Investor&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2019Member_zm0jfA8vNJxe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,185&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;February 2020 Investor&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2020InvestorsMember_zq4ynR9Z7Yk4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,254,755&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt"&gt;TOTAL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdamXVq5ouyc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;163,341,955&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zmwPdX5Yv6Uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Accounting Treatment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When issuing debt or equity securities convertible
into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company
is required to record a beneficial conversion feature (&#x201c;BCF&#x201d;) charge. We had three separate issuances of equity securities
convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes
and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally
classified as a liability when issued due to the down round provision and the removal of the provision requiring liability treatment,
and subsequently reclassified to equity on December 31, 2011, when the 2011 HealthCor Notes were amended, only the accrued interest capitalized
as payment in kind (&#x201c;PIK&#x201d;) since reclassification qualifies under this accounting treatment. We recorded an aggregate of $&lt;span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zh9hr6ryDod3"&gt;2,366,220&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--InterestExpense_pp0p0_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zcD0IT3oBBR5"&gt;5,445,327&lt;/span&gt; in interest for the nine months ended September 30, 2021, and 2020, respectively, related to these transactions. For the
nine months ended September 30, 2021, and 2020, we recorded $&lt;span id="xdx_90D_eus-gaap--PaidInKindInterest_c20210101__20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member_zt2jVsMmRqQj"&gt;2,222,714&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--PaidInKindInterest_c20200101__20200930__srt--CounterpartyNameAxis__custom--HealthCor3Member_znCcqRx9yQfg"&gt;4,219,771&lt;/span&gt;, respectively, of PIK related to the notes included
in the HealthCor Purchase Agreement. The face amount of the 2011 HealthCor Note and 2012 HealthCor Note, and 2014 HealthCor Notes, the
Fourteenth Amendment Notes and the Eighth Amendment Notes and all accrued PIK interest also qualify for BCF treatment as discussed above.
Under the accounting standards, we determined that the restructuring of the HealthCor notes, pursuant to the terms of the Allonge 3 Amendment
Notes, resulted in a troubled debt restructuring. As the future cash flows were greater than the carrying amount of the debt at the date
of the amendment, we accounted for the change prospectively using the new effective interest rate. During the nine months ended September
30, 2021, and 2020, we recorded a BCF of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210101__20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member_z4q4AEk0ZN1d" title="Beneficial conversion feature"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20200930__srt--CounterpartyNameAxis__custom--HealthCor3Member_zlrGP1wKDzv"&gt;0&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Warrants were issued with the Fourth, Fifth, Eighth,
Ninth, and Allonge 3 Amendment Notes and the proceeds were allocated to the instruments based on relative fair value as the warrants did
not contain any features requiring liability treatment and therefore were classified as equity. At each amendment date, the warrants were
recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt discounts are amortized into interest expense
each period under the effective interest method. The value allocated to the Fourth Amendment Warrants was $&lt;span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__srt--CounterpartyNameAxis__custom--HealthCor6Member_zcsopr5YN8ea" title="Debt discount"&gt;1,146,732&lt;/span&gt;. The value allocated
to the Fifth Amendment Warrants was $&lt;span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__srt--CounterpartyNameAxis__custom--HealthCor7Member_zyvQ3nF0ghF"&gt;1,093,105&lt;/span&gt;.&#160;The value allocated to the Eighth Amendment Warrants was $&lt;span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__srt--CounterpartyNameAxis__custom--HealthCor10Member_zrJkiqlQ7wee"&gt;16,000&lt;/span&gt;. The value allocated
to the Ninth Amendment Warrants was $&lt;span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__srt--CounterpartyNameAxis__custom--HealthCorNinthAmedmentPurchaseAgreementMember_zdoKfjQaA3D8"&gt;378,000&lt;/span&gt;.&#160;The value allocated to the Allonge 3 Amendment Warrants was $&lt;span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zrrwuqtu0pt8"&gt;420,000&lt;/span&gt;.&#160;&lt;/p&gt;

</crvw:AgreementWithHealthcorTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="0"
      unitRef="USD">9316000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member"
      decimals="0"
      unitRef="USD">10684000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember">2021-04-20</us-gaap:DebtInstrumentMaturityDate>
    <crvw:IssuanceOfWarrants
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      unitRef="Shares">5488456</crvw:IssuanceOfWarrants>
    <crvw:IssuanceOfWarrants
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member"
      decimals="INF"
      unitRef="Shares">6294403</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_FirstFiveYearNotePeriodMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_SecondFiveYearNotePeriodMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2012-01-31_custom_HealthCor4Member_custom_ConvertibleDebt4Member"
      decimals="0"
      unitRef="USD">2329000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2012-01-31_custom_HealthCor4Member_custom_ConvertibleDebt5Member"
      decimals="0"
      unitRef="USD">2671000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2014-01-16_custom_HealthCor6Member_custom_ConvertibleDebt7Member"
      decimals="0"
      unitRef="USD">2329000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2014-01-16_custom_HealthCor6Member_custom_ConvertibleDebt6Member"
      decimals="0"
      unitRef="USD">2671000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2014-01-152014-01-16_custom_HealthCor6Member_us-gaap_ConvertibleDebtMember">2024-01-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2014-12-04_custom_HealthCor7Member"
      decimals="0"
      unitRef="USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2014-12-04_custom_HealthCor7Member"
      decimals="INF"
      unitRef="USDPShares">0.52</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <crvw:IssuanceOfWarrants
      contextRef="From2014-12-032014-12-04_custom_HealthCor7Member"
      decimals="INF"
      unitRef="Shares">3692308</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2014-12-04_custom_HealthCor7Member"
      decimals="INF"
      unitRef="USDPShares">0.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2014-12-032014-12-04_custom_HealthCor7Member">2025-02-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-02-23_custom_HealthCor10Member"
      decimals="0"
      unitRef="USD">2050000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2018-02-23_custom_HealthCor10Member"
      decimals="INF"
      unitRef="USDPShares">0.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <crvw:IssuanceOfWarrants
      contextRef="From2018-02-222018-02-23_custom_HealthCor10Member"
      decimals="INF"
      unitRef="Shares">512500</crvw:IssuanceOfWarrants>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-02-222018-02-23_custom_HealthCor10Member">2028-02-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Pure">1.20</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember_custom_WarrantsMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <crvw:NetProceedsToBeRetainedFromSaleOfHospitalAssets
      contextRef="From2018-07-092018-07-10_custom_HealthCorNinthAmedmentPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">50000</crvw:NetProceedsToBeRetainedFromSaleOfHospitalAssets>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-07-13_custom_HealthCorTenthAmendmentMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2018-07-13_custom_HealthCorTenthAmendmentMember"
      decimals="INF"
      unitRef="USDPShares">0.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-07-122018-07-13_custom_HealthCorTenthAmendmentMember">2028-07-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-15_custom_HealthCor14Member_custom_HealthCorNewInvestors1Member"
      decimals="0"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-05-15_custom_HealthCor14Member_custom_HealthCorNewInvestors1Member"
      decimals="INF"
      unitRef="USDPShares">0.03</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-05-142019-05-15_custom_HealthCor14Member_custom_HealthCorNewInvestors1Member">2029-05-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_HealthCorThirteenMember_custom_HealthCorNewInvestorsOne1Member_custom_ThirteenthAmendmentNoteMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-02-06_custom_HealthCorThirteenMember_custom_HealthCorNewInvestorsOne1Member_custom_ThirteenthAmendmentNoteMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2021-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2022-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">2022-01-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">2022-04-20</us-gaap:DebtInstrumentMaturityDate>
    <crvw:IssuanceOfWarrants
      contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="Shares">2000000</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember">2031-04-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <crvw:ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_894_ecustom--ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock_z0BfPQj3ESul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zeEBCNxO8zT2"&gt;Below is a summary of the total underlying shares
of common stock related to HealthCor and related investors&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -10pt"&gt;&lt;b&gt;Investor Group&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Underlying
    Shares of Common Stock&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -10pt; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify; padding-left: 0pt"&gt;2014 HealthCor Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2014Member_z80vakQwGvc5" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;30,222,101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2015 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2015Member_zv07FfeOQaS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,879,399&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2015 HealthCor Notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2015Member_zmcwKoNknX6b" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,175,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;February 2018 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2018InvestorsMember_zlEbi3VzAFe8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,866,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;July 2018 Investors&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--July2018InvestorsMember_zqAAd5MCALi6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,709,949&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;2019 Investor&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2019Member_zm0jfA8vNJxe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,185&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0pt"&gt;February 2020 Investor&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2020InvestorsMember_zq4ynR9Z7Yk4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,254,755&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0pt"&gt;TOTAL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pii_uShares_c20210930__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdamXVq5ouyc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;163,341,955&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</crvw:ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2014Member"
      decimals="INF"
      unitRef="Shares">30222101</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2015Member"
      decimals="INF"
      unitRef="Shares">20879399</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2015Member"
      decimals="INF"
      unitRef="Shares">4175882</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2018InvestorsMember"
      decimals="INF"
      unitRef="Shares">63866684</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_July2018InvestorsMember"
      decimals="INF"
      unitRef="Shares">29709949</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2019Member"
      decimals="INF"
      unitRef="Shares">2233185</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2020InvestorsMember"
      decimals="INF"
      unitRef="Shares">12254755</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2021-09-30_custom_HealthCor3Member_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">163341955</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-09-30_custom_Notes2011Member"
      decimals="0"
      unitRef="USD">2366220</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-09-30_custom_Notes2011Member"
      decimals="0"
      unitRef="USD">5445327</us-gaap:InterestExpense>
    <us-gaap:PaidInKindInterest
      contextRef="From2021-01-012021-09-30_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">2222714</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2020-01-012020-09-30_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">4219771</us-gaap:PaidInKindInterest>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2021-01-012021-09-30_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-09-30_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-09-30_custom_HealthCor6Member"
      decimals="0"
      unitRef="USD">1146732</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-09-30_custom_HealthCor7Member"
      decimals="0"
      unitRef="USD">1093105</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-09-30_custom_HealthCor10Member"
      decimals="0"
      unitRef="USD">16000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-09-30_custom_HealthCorNinthAmedmentPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">378000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-09-30_custom_HealthCorNoteExtensionsMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80C_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zsccnb1pVfA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 12 &#x2013; &lt;span id="xdx_826_zOkhVmyPyhT2"&gt;JOINT VENTURE AGREEMENT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 31, 2019, the Company and Rockwell
entered into a Second Amendment to the Rockwell Note (the &#x201c;Second Rockwell Note Amendment&#x201d;) pursuant to which Rockwell agreed
to extend the term of the Rockwell Note by one year, to &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zVZlQA6ORzh1" title="Debt maturity date"&gt;December 31, 2020&lt;/span&gt;, and agreed to extend the time to make the quarterly payment
that would otherwise be due on &lt;span id="xdx_908_ecustom--DebtPreviousPaymentDueDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zv827QWDLq9e" title="Debt previous payment due date"&gt;December 31, 2019&lt;/span&gt;, to &lt;span id="xdx_90C_ecustom--DebtRevisedPaymentDueDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zCU6eSE9EBx6" title="Debt revised payment due date"&gt;January 31, 2020&lt;/span&gt;. We have evaluated the Second Amendment to the Rockwell Note under
ASC 470 and determined that the amendment should be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 31, 2020, the Company and Rockwell
entered into a Third Amendment to the Rockwell Note (the &#x201c;Third Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed
to extend the time to make the quarterly payment that would otherwise be due on&lt;span id="xdx_909_ecustom--DebtPreviousPaymentDueDate_dd_c20200130__20200131__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--ThirdRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zV3z7m27pFWk"&gt; January 31, 2020&lt;/span&gt;, (per the Second Rockwell Note Amendment)
to &lt;span id="xdx_90F_ecustom--DebtRevisedPaymentDueDate_dd_c20200130__20200131__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--ThirdRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zCqX1vXLxHo"&gt;February 10, 2020&lt;/span&gt;. We have evaluated the Third Amendment to the Rockwell Note under ASC 470 and determined that the amendment should
be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of March 31, 2020, the Company and
Rockwell entered into a Fourth Amendment to the Rockwell Note (the &#x201c;Fourth Rockwell Note Amendment&#x201d;), pursuant to which Rockwell
agreed to extend the time to make the quarterly payment that would otherwise be due on &lt;span id="xdx_900_ecustom--DebtPreviousPaymentDueDate_dd_c20200330__20200331__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FourthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zT3UPjxSKFGf"&gt;March 31, 2020&lt;/span&gt;, to &lt;span id="xdx_903_ecustom--DebtRevisedPaymentDueDate_dd_c20200330__20200331__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FourthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zLyH9TkyTMMd"&gt;April 16, 2020&lt;/span&gt;. We have evaluated
the Fourth Amendment to the Rockwell Note under ASC 470 and determined that the amendment should be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 31, 2020, the Company and Rockwell
entered a Fifth Amendment to the Rockwell Note (the &#x201c;Fifth Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed (i)
to extend the term of the Promissory Note by one (&lt;span id="xdx_90F_ecustom--DebtInstrumentTermExtensionPeriod_dtY_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_z3HIBlGMJvFj" title="Extension period"&gt;1&lt;/span&gt;) year and continue the quarterly principal payments through &lt;span id="xdx_908_ecustom--DebtInstrumentDateOfFinalRequiredQuarterlyPayment_dd_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zKsP3EQrPxsl" title="Date of final required quarterly payment"&gt;September 30, 2021&lt;/span&gt;, with
the final balloon payment due on &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zy8Gp4odH8qk"&gt;December 31, 2021&lt;/span&gt;, and (ii) that the quarterly principal payment that would otherwise be due on &lt;span id="xdx_905_ecustom--DebtInstrumentPriorDueDateOfQuarterlyPayment_dd_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zB3f0MMa0S3h" title="Prior due date of quarterly payment"&gt;December
31, 2020&lt;/span&gt;, will not be required to be made until the final balloon payment due date. We have evaluated the Fourth Amendment to the Rockwell
Note under ASC 470 and determined that the amendment should be treated as a debt modification.&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-12-31</us-gaap:DebtInstrumentMaturityDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2019-12-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-01-31</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-01-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-02-10</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-03-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-04-16</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtInstrumentTermExtensionPeriod contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">P1Y</crvw:DebtInstrumentTermExtensionPeriod>
    <crvw:DebtInstrumentDateOfFinalRequiredQuarterlyPayment contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2021-09-30</crvw:DebtInstrumentDateOfFinalRequiredQuarterlyPayment>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2021-12-31</us-gaap:DebtInstrumentMaturityDate>
    <crvw:DebtInstrumentPriorDueDateOfQuarterlyPayment contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-12-31</crvw:DebtInstrumentPriorDueDateOfQuarterlyPayment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zV0fWnxQu6e6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 13 &#x2013; &lt;span id="xdx_829_zafTwREvBXF9"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Amendment to Commercial Lease Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 4, 2020, we entered into the Fourth Amendment
to Commercial Lease Agreement (the &#x201c;Lease Extension&#x201d;), wherein we extended the Lease through &lt;span id="xdx_90B_eus-gaap--LeaseExpirationDate1_dd_c20200303__20200304_zjeOmebxWLN6" title="Expiration of lease"&gt;August 31, 2025&lt;/span&gt;. The Lease Extension
contains a renewal provision under which we may renew the Lease for an additional &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20200304_zl3SjAjUAmhd" title="Lease renewal term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1082"&gt;five-year&lt;/span&gt;&lt;/span&gt; period under the same terms and conditions.
We believe that these premises are adequate and sufficient for our current needs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Payroll Protection Program&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 10, 2020, the Company received loan proceeds
in the amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20200410__us-gaap--TypeOfArrangementAxis__custom--PayrollProtectionProgramMember__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zDFwADxDZOC3" title="Loan amount"&gt;781,800&lt;/span&gt; pursuant to a promissory note agreement (the &#x201c;Promissory Note&#x201d;) with a bank under the Paycheck Protection
Program (&#x201c;PPP&#x201d;). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;),
provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business.
The Promissory Note has a loan maturity of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200409__20200410__us-gaap--TypeOfArrangementAxis__custom--PayrollProtectionProgramMember__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zwVV9vYNTy14" title="Maturity date"&gt;April 10, 2022&lt;/span&gt;, a stated interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20200409__20200410__us-gaap--TypeOfArrangementAxis__custom--PayrollProtectionProgramMember__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zwzar83cBDe6" title="Interest rate"&gt;1.0&lt;/span&gt;% per annum, and has payments of principal and
interest that are due monthly after an initial six-month deferral period where interest accrues, but no payments are due. The Promissory
Note provides for customary events of default, including, among others, those relating to failure to make payment when due and breaches
of representations. The Company may prepay the principal of the Promissory Note at any time without incurring any prepayment charges.
The loan is subject to all the terms and conditions applicable under the PPP and is subject to review by the Small Business Association
(the &#x201c;SBA&#x201d;) for compliance with program requirements, including the Company&#x2019;s certification that the current economic
uncertainty made the PPP loan request necessary to support ongoing operations and the Company&#x2019;s obtaining approval from the SBA
for the private placement equity transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2020, the Payroll Protection Program Flexibility
Act (&#x201c;PPPFA&#x201d;) was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA,
the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years.
The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The loan&#x2019;s principal and accrued interest
were forgivable to the extent that the Company initially qualified for the loan and the proceeds were used for eligible purposes, subject
to certain limitations, and that the Company maintains its payroll levels over a twenty-four-week period following the loan date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As the legal form of the Promissory Note was a
debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, Debt and recorded a liability
of $&lt;span id="xdx_909_eus-gaap--LongTermDebtCurrent_iI_c20200410__us-gaap--TypeOfArrangementAxis__custom--PayrollProtectionProgramMember__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zZwQGNzgsN1j" title="Debt liability"&gt;781,800&lt;/span&gt; in the consolidated balance sheet upon receipt of the loan proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applied for forgiveness, and on November
20, 2020, we received confirmation from our bank that the Promissory Note was forgiven by the SBA. The loan balance plus accrued interest
of $&lt;span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20200101__20201231_zJFQDONTChN5" title="Gain on extinguishment of debt"&gt;786,889&lt;/span&gt; was recorded as a gain on extinguishment of debt in the December 31, 2020, consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The SBA has created an audit safe harbor for any
PPP loan borrower that, together with its affiliates, received PPP loans with an original amount of less than $2 million. The safe harbor
is designed to protect a small borrower from a PPP audit based on its good faith certification. However, the government may still decide
to audit a PPP loan for other purposes, such as possible misuse of PPP funds. The Company has not been notified of an audit by the SBA.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-03-032020-03-04">2025-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember"
      decimals="0"
      unitRef="USD">781800</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-04-092020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember">2022-04-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-04-092020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember"
      decimals="INF"
      unitRef="Pure">0.010</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2020-04-10_custom_PayrollProtectionProgramMember_custom_PPPLoanMember"
      decimals="0"
      unitRef="USD">781800</us-gaap:LongTermDebtCurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">786889</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_zLNsJdyGBhNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 14 -- &lt;span id="xdx_828_zix79f2R4CH6"&gt;LEASE&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89F_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z7adSOQIBygi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;),
operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting
of office space with remaining lease term of &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20210930_zosFrvvjLt4f" title="Remaining lease term"&gt;18 &lt;/span&gt;months. We adopted ASC 842 under the modified retrospective transition method for all
long-term operating leases as of January 1, 2019. &lt;span id="xdx_8B3_zVOBMEbWsE5a"&gt;The cumulative impact of the adoption of ASC 842 to the condensed consolidated balance
sheet as of September 30, 2021, was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: justify; padding-left: 0pt"&gt;Operating Lease Asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20210930_zHdw7gTFqwFb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Operating Lease Liability-ST&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20210930_zOy2veeVG9hj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;159,346&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Operating Lease Liability-LT&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20210930_zvSmA7IwRJsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,309&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z2eNdTnrbqEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The adoption of ASC 842 did not result in an adjustment
to retained earnings. The adoption of ASC 842 represents a change in accounting principle.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 8, 2009, we entered into a Commercial
Lease Agreement (the &#x201c;Lease&#x201d;) for &lt;span id="xdx_908_ecustom--AreaOfLeasedProperty_iI_usqft_c20090908_z3a1pSRdTVKj" title="Area of lease"&gt;10,578&lt;/span&gt; square feet of office and warehouse space expiring on &lt;span id="xdx_90D_eus-gaap--LeaseExpirationDate1_dd_c20090907__20090908_zpNBDTwjCV77"&gt;June 30, 2015&lt;/span&gt;. On March 4,
2020, we entered into the Fourth Amendment to Commercial Lease Agreement (the &#x201c;Lease Extension&#x201d;), wherein we extended the
Lease through &lt;span id="xdx_90C_eus-gaap--LeaseExpirationDate1_dd_c20200303__20200304_zT17v8Hl7B3c" title="Expiration of lease"&gt;August 31, 2025&lt;/span&gt;.&#160; The Lease Extension contains a renewal provision under which the Lease has been extended for an additional
&lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20200304_zORu9wBCaDEj" title="Lease renewal term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;five-year&lt;/span&gt;&lt;/span&gt; period under the same terms and conditions of the original Lease Agreement. Management has identified this extension as a reassessment
event, as we have elected to exercise the Lease Extension option even though the Company had previously determined that it was not reasonably
certain to do so.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has reassessed the discount rate at
the remeasurement date, at &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20210930_zC0k2pKBMWzl" title="Discount rate"&gt;14.8&lt;/span&gt;% and the Company has remeasured its ROU asset and lease liability on our balance sheet using the discount
rate that applies as of the date of the reassessment event to remeasure its Operating lease asset and lease liability. The reassessment
is based on the remaining lease term and lease payments. The Company has further concluded that the Lease Extension has no effects on
the classification of the Lease. Rent expense for the nine months ended September 30, 2021, and 2020 was $&lt;span id="xdx_902_eus-gaap--OperatingLeaseCost_c20210101__20210930_zzhqnyNu2C4l" title="Rent expense"&gt;213,674&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseCost_c20200101__20200930_zV4GMmO8CMai"&gt;223,868&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Lease Position&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock_zkRFVZRcvhl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zk6TFT1RiPic"&gt;Operating lease asset and liability for our operating
lease were recorded in the condensed consolidated balance sheet as follows&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210930_zpLokwoU3BK2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_zS4Hh1lhWgw2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maLAzmIW_zfvWQG1yrQV2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LeaseAssets_i01TI_mtLAzmIW_zVgeighpCpE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total lease asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAbstract_iB_zciMAYjN7udc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_ztWFqzGwlwg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Current liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maOLLz5MW_zOJSXZj6AFBk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;159,346&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zhes4wHH8TAk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Long-term liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_zlr78wV93mg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;Operating lease liability, net of current
    portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,309&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLz5MW_zOUtmcH3pm3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;635,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zu43xdKd6pdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;










&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmRrmhp0Z8L3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BE_zFusOFMOi3ck"&gt;Future lease payments included in the measurement of operating lease
liability on the condensed consolidated balance sheet as of September 30, 2021, for the following five fiscal years and thereafter as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;Quarter ended &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20210930_z3oGoVTNvII8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Operating &lt;br/&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzlji_zEZ5E1Ixg723" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;51,325&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzlji_zOklwuulG2Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;208,379&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzlji_zBpg9UQdsZPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214,631&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzlji_zEMyOS4POAC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;221,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzlji_znYzqzls6rI6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;150,679&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzlji_zC20xHjEQUL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;846,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zmhxjZciocba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Less effects of discounting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(210,428&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zxfb7R1k3T2h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;635,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zFtyldObOgKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Cash Flows&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--LesseeOperatingLeaseCashFlowInformationTableTextBlock_zsCMnhBKf2G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zQPwodmXYn0b"&gt;The table below presents certain information related
to the cash flows for the Company&#x2019;s operating lease for the nine months ended September 30, 2021&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20210101__20210930_zdTgUklBMFCg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Nine Months Ended &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zjNjYTSE8gGk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt; text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01N_di_zGgUx5GujUea" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 70%; text-align: justify; padding-bottom: 2.5pt"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(75,634&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zDLJ759eI89l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89F_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z7adSOQIBygi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;),
operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting
of office space with remaining lease term of &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20210930_zosFrvvjLt4f" title="Remaining lease term"&gt;18 &lt;/span&gt;months. We adopted ASC 842 under the modified retrospective transition method for all
long-term operating leases as of January 1, 2019. &lt;span id="xdx_8B3_zVOBMEbWsE5a"&gt;The cumulative impact of the adoption of ASC 842 to the condensed consolidated balance
sheet as of September 30, 2021, was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
    &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: justify; padding-left: 0pt"&gt;Operating Lease Asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20210930_zHdw7gTFqwFb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Operating Lease Liability-ST&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20210930_zOy2veeVG9hj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;159,346&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"&gt;Operating Lease Liability-LT&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20210930_zvSmA7IwRJsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,309&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2021-09-30">P18M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">582594</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">159346</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">476309</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <crvw:AreaOfLeasedProperty contextRef="AsOf2009-09-08" decimals="INF" unitRef="sqft">10578</crvw:AreaOfLeasedProperty>
    <us-gaap:LeaseExpirationDate1 contextRef="From2009-09-072009-09-08">2015-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-03-032020-03-04">2025-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2021-09-30" decimals="INF" unitRef="Pure">0.148</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">213674</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">223868</us-gaap:OperatingLeaseCost>
    <crvw:LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89E_ecustom--LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock_zkRFVZRcvhl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zk6TFT1RiPic"&gt;Operating lease asset and liability for our operating
lease were recorded in the condensed consolidated balance sheet as follows&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210930_zpLokwoU3BK2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_zS4Hh1lhWgw2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maLAzmIW_zfvWQG1yrQV2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LeaseAssets_i01TI_mtLAzmIW_zVgeighpCpE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total lease asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;582,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAbstract_iB_zciMAYjN7udc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"&gt;Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_ztWFqzGwlwg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Current liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maOLLz5MW_zOJSXZj6AFBk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;159,346&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zhes4wHH8TAk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"&gt;Long-term liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_zlr78wV93mg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;Operating lease liability, net of current
    portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;476,309&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLz5MW_zOUtmcH3pm3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;635,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</crvw:LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">582594</us-gaap:OperatingLeaseRightOfUseAsset>
    <crvw:LeaseAssets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">582594</crvw:LeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">159346</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">476309</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">635655</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmRrmhp0Z8L3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BE_zFusOFMOi3ck"&gt;Future lease payments included in the measurement of operating lease
liability on the condensed consolidated balance sheet as of September 30, 2021, for the following five fiscal years and thereafter as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;Quarter ended &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20210930_z3oGoVTNvII8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Operating &lt;br/&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzlji_zEZ5E1Ixg723" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;51,325&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzlji_zOklwuulG2Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;208,379&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzlji_zBpg9UQdsZPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214,631&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzlji_zEMyOS4POAC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;221,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzlji_znYzqzls6rI6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;150,679&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzlji_zC20xHjEQUL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;846,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zmhxjZciocba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Less effects of discounting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(210,428&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zxfb7R1k3T2h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;635,655&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">51325</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">208379</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">214631</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">221069</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150679</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">846083</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">210428</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">635655</us-gaap:OperatingLeaseLiability>
    <crvw:LesseeOperatingLeaseCashFlowInformationTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89F_ecustom--LesseeOperatingLeaseCashFlowInformationTableTextBlock_zsCMnhBKf2G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zQPwodmXYn0b"&gt;The table below presents certain information related
to the cash flows for the Company&#x2019;s operating lease for the nine months ended September 30, 2021&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20210101__20210930_zdTgUklBMFCg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Nine Months Ended &lt;br/&gt;September 30, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zjNjYTSE8gGk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt; text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01N_di_zGgUx5GujUea" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 70%; text-align: justify; padding-bottom: 2.5pt"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;(75,634&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</crvw:LesseeOperatingLeaseCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">75634</us-gaap:OperatingLeasePayments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000859"
          xlink:label="Fact000859"
          xlink:type="locator"/>
        <link:footnote id="Footnote000873" xlink:label="Footnote000873" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Salary for Steve Johnson, CEO, between February 15, 2018, and September 30, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000859"
          xlink:to="Footnote000873"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000860"
          xlink:label="Fact000860"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000860"
          xlink:to="Footnote000873"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000865"
          xlink:label="Fact000865"
          xlink:type="locator"/>
        <link:footnote id="Footnote000874" xlink:label="Footnote000874" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Renewal of directors and officer&#x2019;s insurance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000865"
          xlink:to="Footnote000874"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000866"
          xlink:label="Fact000866"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000866"
          xlink:to="Footnote000874"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
